BG60462B1 - Хуманизирани антитела - Google Patents

Хуманизирани антитела Download PDF

Info

Publication number: BG60462B1
Authority: BG; Bulgaria
Prior art keywords: antibody; cdr; residues; donor; cdr grafted
Prior art date: 1989-12-21

Application number

BG95018A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG95018A (bg

Inventor

John R Adair

Diljeet S Athwal

John S Emtage

Original Assignee

Celltech Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-12-21

Filing date

1991-08-20

Publication date

1995-04-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10668300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG60462(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-08-20 Application filed by Celltech Ltd filed Critical Celltech Ltd

1993-12-24 Publication of BG95018A publication Critical patent/BG95018A/bg

1995-04-28 Publication of BG60462B1 publication Critical patent/BG60462B1/bg

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Zoology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BG95018A 1989-12-21 1991-08-20 Хуманизирани антитела BG60462B1 (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB898928874A GB8928874D0 (en)	1989-12-21	1989-12-21	Humanised antibodies
PCT/GB1990/002017 WO1991009967A1 (en)	1989-12-21	1990-12-21	Humanised antibodies

Publications (2)

Publication Number	Publication Date
BG95018A BG95018A (bg)	1993-12-24
BG60462B1 true BG60462B1 (bg)	1995-04-28

Family

ID=10668300

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG95018A BG60462B1 (bg)	1989-12-21	1991-08-20	Хуманизирани антитела

Country Status (21)

Country	Link
US (11)	US5929212A (fi)
EP (5)	EP0460178B1 (fi)
JP (4)	JPH04505398A (fi)
KR (3)	KR100191152B1 (fi)
AT (4)	ATE159299T1 (fi)
AU (4)	AU631481B2 (fi)
BG (1)	BG60462B1 (fi)
BR (1)	BR9007197A (fi)
CA (3)	CA2046904C (fi)
DE (4)	DE69033857T2 (fi)
DK (4)	DK0460171T3 (fi)
ES (4)	ES2165864T3 (fi)
FI (4)	FI108777B (fi)
GB (4)	GB8928874D0 (fi)
GR (2)	GR3017734T3 (fi)
HU (4)	HU215383B (fi)
NO (5)	NO913229L (fi)
RO (3)	RO114980B1 (fi)
RU (1)	RU2112037C1 (fi)
WO (3)	WO1991009967A1 (fi)
ZA (1)	ZA9110129B (fi)

Families Citing this family (1357)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5800815A (en) *	1903-05-05	1998-09-01	Cytel Corporation	Antibodies to P-selectin and their uses
CU22545A1 (es) *	1994-11-18	1999-03-31	Centro Inmunologia Molecular	Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US6054561A (en) *	1984-02-08	2000-04-25	Chiron Corporation	Antigen-binding sites of antibody molecules specific for cancer antigens
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US5449760A (en) *	1987-12-31	1995-09-12	Tanox Biosystems, Inc.	Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US20030225254A1 (en)	1989-08-07	2003-12-04	Rathjen Deborah Ann	Tumour necrosis factor binding ligands
WO1991002078A1 (en)	1989-08-07	1991-02-21	Peptide Technology Ltd	Tumour necrosis factor binding ligands
US6406696B1 (en)	1989-10-27	2002-06-18	Tolerance Therapeutics, Inc.	Methods of stimulating the immune system with anti-CD3 antibodies
EP0839536A1 (en) *	1989-10-27	1998-05-06	Arch Development Corporation	Methods and compositions for promoting immunopotentiation
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US6750325B1 (en) *	1989-12-21	2004-06-15	Celltech R&D Limited	CD3 specific recombinant antibody
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US7037496B2 (en)	1989-12-27	2006-05-02	Centocor, Inc.	Chimeric immunoglobulin for CD4 receptors
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
US5770429A (en) *	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
GB9020282D0 (en)	1990-09-17	1990-10-31	Gorman Scott D	Altered antibodies and their preparation
GB9021679D0 (en) *	1990-10-05	1990-11-21	Gorman Scott David	Antibody preparation
GB9022543D0 (en) *	1990-10-17	1990-11-28	Wellcome Found	Antibody production
US6399062B1 (en) *	1990-11-06	2002-06-04	The United States Of America As Represented By The Secretary Of The Navy	Murine monoclonal antibody protective against Plasmodium vivax malaria
CA2073031C (en) *	1990-11-27	2002-10-01	Linda C. Burkly	Anti-cd4 antibody homologs useful in prophylaxis and treatment of aids, arc and hiv infection
US5994510A (en) *	1990-12-21	1999-11-30	Celltech Therapeutics Limited	Recombinant antibodies specific for TNFα
GB9109645D0 (en) *	1991-05-03	1991-06-26	Celltech Ltd	Recombinant antibodies
GB9104498D0 (en) *	1991-03-04	1991-04-17	Ks Biomedix Ltd	Antibody
US6277969B1 (en)	1991-03-18	2001-08-21	New York University	Anti-TNF antibodies and peptides of human tumor necrosis factor
US5698195A (en) *	1991-03-18	1997-12-16	New York University Medical Center	Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US5656272A (en) *	1991-03-18	1997-08-12	New York University Medical Center	Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
EP1681305A3 (en) *	1991-03-18	2008-02-27	New York University	Monoclonal and chimeric antibodies specific for human tumor necrosis factor
US5919452A (en) *	1991-03-18	1999-07-06	New York University	Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US7192584B2 (en)	1991-03-18	2007-03-20	Centocor, Inc.	Methods of treating psoriasis with anti-TNF antibodies
US6284471B1 (en)	1991-03-18	2001-09-04	New York University Medical Center	Anti-TNFa antibodies and assays employing anti-TNFa antibodies
KR100249937B1 (ko) *	1991-04-25	2000-04-01	나가야마 오사무	인간 인터루킨-6 수용체에 대한 재구성 인간 항체
US6797492B2 (en)	1991-05-17	2004-09-28	Merck & Co., Inc.	Method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) *	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
US6800738B1 (en) *	1991-06-14	2004-10-05	Genentech, Inc.	Method for making humanized antibodies
DE122004000008I1 (de)	1991-06-14	2005-06-09	Genentech Inc	Humanisierter Heregulin Antikörper.
GB9115364D0 (en)	1991-07-16	1991-08-28	Wellcome Found	Antibody
US6329509B1 (en)	1991-08-14	2001-12-11	Genentech, Inc.	Anti-IgE antibodies
US6685939B2 (en)	1991-08-14	2004-02-03	Genentech, Inc.	Method of preventing the onset of allergic disorders
DE69230545T2 (de) *	1991-08-21	2000-07-06	Novartis Ag, Basel	Antikörperderivate
AU669124B2 (en) *	1991-09-18	1996-05-30	Kyowa Hakko Kirin Co., Ltd.	Process for producing humanized chimera antibody
GB9120467D0 (en) *	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
GB9122820D0 (en) *	1991-10-28	1991-12-11	Wellcome Found	Stabilised antibodies
GB9125979D0 (en) *	1991-12-06	1992-02-05	Wellcome Found	Antibody
JPH05244982A (ja) *	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
WO1993012220A1 (en) *	1991-12-12	1993-06-24	Berlex Laboratories, Inc.	RECOMBINANT AND CHIMERIC ANTIBODIES TO c-erbB-2
US5635177A (en)	1992-01-22	1997-06-03	Genentech, Inc.	Protein tyrosine kinase agonist antibodies
US5837822A (en) *	1992-01-27	1998-11-17	Icos Corporation	Humanized antibodies specific for ICAM related protein
ATE295420T1 (de) *	1992-02-06	2005-05-15	Chiron Corp	Marker für krebs und biosynthetisches bindeprotein dafür
GB9206422D0 (en)	1992-03-24	1992-05-06	Bolt Sarah L	Antibody preparation
US7381803B1 (en) *	1992-03-27	2008-06-03	Pdl Biopharma, Inc.	Humanized antibodies against CD3
EP0563487A1 (en)	1992-03-31	1993-10-06	Laboratoire Europeen De Biotechnologie S.A.	Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5646253A (en) *	1994-03-08	1997-07-08	Memorial Sloan-Kettering Cancer Center	Recombinant human anti-LK26 antibodies
US6033667A (en) *	1992-05-05	2000-03-07	Cytel Corporation	Method for detecting the presence of P-selectin
DE4225853A1 (de) *	1992-08-05	1994-02-10	Behringwerke Ag	Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung
US6042828A (en) *	1992-09-07	2000-03-28	Kyowa Hakko Kogyo Co., Ltd.	Humanized antibodies to ganglioside GM2
US5639641A (en) *	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5958708A (en) *	1992-09-25	1999-09-28	Novartis Corporation	Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) *	1992-09-25	2000-05-23	Novartis Corporation	Reshaped monoclonal antibodies against an immunoglobulin isotype
GB9221654D0 (en) *	1992-10-15	1992-11-25	Scotgen Ltd	Recombinant human anti-cytomegalovirus antibodies
GB9223377D0 (en) *	1992-11-04	1992-12-23	Medarex Inc	Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5804187A (en) *	1992-11-16	1998-09-08	Cancer Research Fund Of Contra Costa	Modified antibodies with human milk fat globule specificity
NZ261259A (en) *	1993-01-12	1996-12-20	Biogen Inc	Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
US6491916B1 (en)	1994-06-01	2002-12-10	Tolerance Therapeutics, Inc.	Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5885573A (en) *	1993-06-01	1999-03-23	Arch Development Corporation	Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6180377B1 (en) *	1993-06-16	2001-01-30	Celltech Therapeutics Limited	Humanized antibodies
WO1995001997A1 (en) *	1993-07-09	1995-01-19	Smithkline Beecham Corporation	RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
JPH09511220A (ja) *	1993-11-10	1997-11-11	ブリストル‐マイヤーズスクイブカンパニー	バクテリアによって誘発される炎症性疾患の治療
US6214973B1 (en) *	1993-11-19	2001-04-10	Chugai Seiyaku Kabushiki Kaisha	Reshaped human antibody to human medulloblastoma cells
GB9325182D0 (en) *	1993-12-08	1994-02-09	T Cell Sciences Inc	Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US5686070A (en) *	1994-03-03	1997-11-11	Genentech, Inc.	Methods for treating bacterial pneumonia
US5597710A (en) *	1994-03-10	1997-01-28	Schering Corporation	Humanized monoclonal antibodies against human interleukin-4
WO1995026403A1 (en) *	1994-03-29	1995-10-05	Celltech Therapeutics Limited	Antibodies against e-selectin
WO1995031546A1 (en) *	1994-04-28	1995-11-23	Scotgen Biopharmaceuticals, Inc.	Recombinant human anti-varicella zoster virus antibodies
US5773001A (en) *	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
GB9412230D0 (en) *	1994-06-17	1994-08-10	Celltech Ltd	Interleukin-5 specific recombiant antibodies
USRE39548E1 (en) *	1994-06-17	2007-04-03	Celltech R&D Limited	Interleukin-5 specific recombinant antibodies
US8771694B2 (en) *	1994-08-12	2014-07-08	Immunomedics, Inc.	Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US5874540A (en) *	1994-10-05	1999-02-23	Immunomedics, Inc.	CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US7597886B2 (en)	1994-11-07	2009-10-06	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
GB9424449D0 (en) *	1994-12-02	1995-01-18	Wellcome Found	Antibodies
EP0746619A1 (en)	1994-12-23	1996-12-11	Celltech Therapeutics Limited	Human phosphodiesterase type ivc, and its production and use
ES2196098T3 (es) *	1994-12-28	2003-12-16	Univ Kentucky Res Found	Secuencias anticuerpos anti-idiotipo 3h1 monoclonales relacionadas con el antigeno carcinoembrionico humano.
US6949244B1 (en) *	1995-12-20	2005-09-27	The Board Of Trustees Of The University Of Kentucky	Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US6551593B1 (en)	1995-02-10	2003-04-22	Millennium Pharmaceuticals, Inc.	Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en)	1995-09-01	2010-09-28	Millennium Pharmaceuticals, Inc.	Mucosal vascular addressing and uses thereof
US5795961A (en) *	1995-02-14	1998-08-18	Ludwig Institute For Cancer Research	Recombinant human anti-Lewis b antibodies
US5705154A (en) *	1995-03-08	1998-01-06	Schering Corporation	Humanized monoclonal antibodies against human interleukin-4
US7429646B1 (en)	1995-06-05	2008-09-30	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor-like 2
ATE238066T1 (de) *	1995-05-18	2003-05-15	Ortho Mcneil Pharm Inc	Induktion von immunologischer toleranz unter verwendung von nicht-zellmengeverringernden anti- cd4-antikoepern
US5712374A (en) *	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
DE69632465T2 (de)	1995-06-07	2005-06-23	Ortho-Mcneil Pharmaceutical, Inc.	Cdr-transplantierte antikörper gegen "tissue factor" und verfahren zur deren verwendung
US7060808B1 (en)	1995-06-07	2006-06-13	Imclone Systems Incorporated	Humanized anti-EGF receptor monoclonal antibody
ATE483733T1 (de) *	1995-06-14	2010-10-15	Univ California	Hochaffine humane antikörper gegen tumorantigene
DE19543039C1 (de) *	1995-11-08	1996-11-21	Medac Klinische Spezialpraep	Rekombinante Liganden für das menschliche Zellmembran-Antigen CD30
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
US7888466B2 (en)	1996-01-11	2011-02-15	Human Genome Sciences, Inc.	Human G-protein chemokine receptor HSATU68
MA24512A1 (fr) *	1996-01-17	1998-12-31	Univ Vermont And State Agrienl	Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
BRPI9707379C8 (pt)	1996-02-09	2017-12-12	Abbott Biotech Ltd	composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
US6635743B1 (en)	1996-03-22	2003-10-21	Human Genome Sciences, Inc.	Apoptosis inducing molecule II and methods of use
US7964190B2 (en)	1996-03-22	2011-06-21	Human Genome Sciences, Inc.	Methods and compositions for decreasing T-cell activity
US6107090A (en) *	1996-05-06	2000-08-22	Cornell Research Foundation, Inc.	Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en)	1996-05-06	2000-10-24	Cornell Research Foundation, Inc.	Treatment and diagnosis of cancer
ATE248192T1 (de)	1996-06-07	2003-09-15	Neorx Corp	HUMANISIERTE ANTIKÖRPER DIE AN DAS GLEICHE ANTIGEN WIE ANTIKÖRPER NR-LU-13 BINDEN UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
US7147851B1 (en)	1996-08-15	2006-12-12	Millennium Pharmaceuticals, Inc.	Humanized immunoglobulin reactive with α4β7 integrin
EP0941345A2 (en) *	1996-09-20	1999-09-15	The General Hospital Corporation	Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
UA76934C2 (en) *	1996-10-04	2006-10-16	Chugai Pharmaceutical Co Ltd	Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
US7883872B2 (en)	1996-10-10	2011-02-08	Dyadic International (Usa), Inc.	Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US6037454A (en)	1996-11-27	2000-03-14	Genentech, Inc.	Humanized anti-CD11a antibodies
US6737057B1 (en) *	1997-01-07	2004-05-18	The University Of Tennessee Research Corporation	Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US6455040B1 (en)	1997-01-14	2002-09-24	Human Genome Sciences, Inc.	Tumor necrosis factor receptor 5
DE69837806T3 (de)	1997-01-28	2012-01-05	Human Genome Sciences, Inc.	"death-domain"-enthaltender rezeptor 4 (dr4), ein mitglied der tnf-rezeptor superfamilie, welcher an trail (apo-2l) bindet
US8329179B2 (en)	1997-01-28	2012-12-11	Human Genome Sciences, Inc.	Death domain containing receptor 4 antibodies and methods
US7452538B2 (en)	1997-01-28	2008-11-18	Human Genome Sciences, Inc.	Death domain containing receptor 4 antibodies and methods
US6433147B1 (en)	1997-01-28	2002-08-13	Human Genome Sciences, Inc.	Death domain containing receptor-4
US6541212B2 (en)	1997-03-10	2003-04-01	The Regents Of The University Of California	Methods for detecting prostate stem cell antigen protein
EP0970213B1 (en) *	1997-03-17	2007-01-24	Human Genome Sciences, Inc.	Death domain containing receptor 5
US6872568B1 (en)	1997-03-17	2005-03-29	Human Genome Sciences, Inc.	Death domain containing receptor 5 antibodies
US20020032315A1 (en)	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies
PT1695985E (pt) *	1997-04-07	2011-06-06	Genentech Inc	Métodos para formar anticorpos humanizados por mutagénese aleatória
US20070059302A1 (en)	1997-04-07	2007-03-15	Genentech, Inc.	Anti-vegf antibodies
CN100480269C (zh) *	1997-04-07	2009-04-22	基因技术股份有限公司	抗-血管内皮生长因子的抗体
US6884879B1 (en)	1997-04-07	2005-04-26	Genentech, Inc.	Anti-VEGF antibodies
ATE319745T1 (de)	1997-05-21	2006-03-15	Biovation Ltd	Verfahren zur herstellung von nicht-immunogenen proteinen
US7052873B2 (en)	1997-10-03	2006-05-30	Chugai Seiyaku Kabushiki Kaisha	Natural human antibody
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
TWI239847B (en) *	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
ATE490980T1 (de)	1998-03-19	2010-12-15	Human Genome Sciences	Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
ES2364266T3 (es) *	1998-04-03	2011-08-30	Chugai Seiyaku Kabushiki Kaisha	Anticuerpo humanizado hacia el factor tisular humano (tf) y procedimiento para construir el anticuerpo humanizado.
AU761587B2 (en) *	1998-04-21	2003-06-05	Amgen Research (Munich) Gmbh	CD19xCD3 specific polypeptides and uses thereof
US7244826B1 (en)	1998-04-24	2007-07-17	The Regents Of The University Of California	Internalizing ERB2 antibodies
ES2230848T3 (es) *	1998-04-28	2005-05-01	Smithkline Beecham Corporation	Anticuerpos monoclonales con inmunogenicidad reducida.
US6455677B1 (en) *	1998-04-30	2002-09-24	Boehringer Ingelheim International Gmbh	FAPα-specific antibody with improved producibility
GB9812545D0 (en)	1998-06-10	1998-08-05	Celltech Therapeutics Ltd	Biological products
GB9815909D0 (en) *	1998-07-21	1998-09-16	Btg Int Ltd	Antibody preparation
US6696550B2 (en)	1998-07-23	2004-02-24	Millennium Pharmaceuticals, Inc.	Humanized anti-CCR2 antibodies and methods of use therefor
US6727349B1 (en)	1998-07-23	2004-04-27	Millennium Pharmaceuticals, Inc.	Recombinant anti-CCR2 antibodies and methods of use therefor
US6312689B1 (en)	1998-07-23	2001-11-06	Millennium Pharmaceuticals, Inc.	Anti-CCR2 antibodies and methods of use therefor
EA005682B1 (ru)	1998-10-06	2005-04-28	Марк Аарон Эмалфарб	Трансформированные грибы, в частности рода chrysosporium, способные к синтезу гетерологичных полипептидов
US6160099A (en) *	1998-11-24	2000-12-12	Jonak; Zdenka Ludmila	Anti-human αv β3 and αv β5 antibodies
ES2350454T3 (es)	1998-11-27	2011-01-24	Ucb Pharma S.A.	Composiciones y métodos para incrementar la mineralización de la sustancia ósea.
US20040009535A1 (en)	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
EP1161451A4 (en)	1999-02-26	2006-05-17	Human Genome Sciences Inc	HUMAN ALPHA ENDOKIN AND METHOD FOR ITS USE
US6492497B1 (en) *	1999-04-30	2002-12-10	Cambridge Antibody Technology Limited	Specific binding members for TGFbeta1
US20040013667A1 (en) *	1999-06-25	2004-01-22	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
US6949245B1 (en) *	1999-06-25	2005-09-27	Genentech, Inc.	Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20030086924A1 (en) *	1999-06-25	2003-05-08	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
WO2001021215A1 (en) *	1999-09-22	2001-03-29	Ortho-Mcneil Pharmaceutical, Inc.	Cell based assay
AU784187B2 (en) *	1999-09-30	2006-02-16	Kyowa Hakko Kogyo Co. Ltd.	Human type complementarity determining region transplantation antibody against ganglioside GD3 and derivatives of antibody against ganglioside GD3
US6346249B1 (en) *	1999-10-22	2002-02-12	Ludwig Institute For Cancer Research	Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
US6342587B1 (en) *	1999-10-22	2002-01-29	Ludwig Institute For Cancer Research	A33 antigen specific immunoglobulin products and uses thereof
CU22921A1 (es) *	1999-11-16	2004-02-20	Centro Inmunologia Molecular	Anticuerpos quimérico, humanizado y el fragmento de tipo fv de cadena sencilla que reconoce el antígeno c2. su uso en el diagnóstico y tratamiento de tumores colorrectales
GB0001448D0 (en)	2000-01-21	2000-03-08	Novartis Ag	Organic compounds
US7229619B1 (en)	2000-11-28	2007-06-12	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6656467B2 (en) *	2000-01-27	2003-12-02	Medimmune, Inc.	Ultra high affinity neutralizing antibodies
DE60130538T2 (de) *	2000-02-03	2008-06-12	Millenium Pharmaceuticals, Inc., Cambridge	Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
EP1783227A1 (en) *	2000-02-03	2007-05-09	Millennium Pharmaceuticals, Inc.	Humanized anti-CCR2 antibodies and methods of use therefor
WO2001058949A2 (en)	2000-02-11	2001-08-16	Biogen, Inc.	Heterologous polypeptide of the tnf family
EP3070100B1 (en)	2000-02-24	2021-07-07	Washington University St. Louis	Humanized antibodies that sequester amyloid beta peptide
EP1259547B1 (en) *	2000-03-01	2012-07-11	Medimmune, Inc.	High potency recombinant antibodies and method for producing them
EP1418234A4 (en) *	2000-03-02	2005-03-16	Abgenix Inc	HUMAN MONOCLONAL ANTIBODIES DIRECTED AGAINST OXIDIZED LDL RECEPTORS AND THEIR MEDICAL USE
WO2001070266A2 (en)	2000-03-17	2001-09-27	Millennium Pharmaceuticals, Inc.	Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2
CA2405709A1 (en)	2000-04-12	2001-10-25	Human Genome Sciences, Inc.	Albumin fusion proteins
AU4884001A (en)	2000-04-21	2001-11-07	Fuso Pharmaceutical Ind	Novel collectins
GB0013810D0 (en) *	2000-06-06	2000-07-26	Celltech Chiroscience Ltd	Biological products
US20030031675A1 (en)	2000-06-06	2003-02-13	Mikesell Glen E.	B7-related nucleic acids and polypeptides useful for immunomodulation
AU2001282856A1 (en)	2000-06-15	2001-12-24	Human Genome Sciences, Inc.	Human tumor necrosis factor delta and epsilon
WO2002002641A1 (en)	2000-06-16	2002-01-10	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to blys
UA81743C2 (uk) *	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
GB0020685D0 (en)	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
US7060802B1 (en)	2000-09-18	2006-06-13	The Trustees Of Columbia University In The City Of New York	Tumor-associated marker
IL155340A0 (en)	2000-10-13	2003-11-23	Biogen Inc	HUMANIZED ANTI LYMPHOTOXIN-beta-RECEPTOR ANTIBODIES
TWI327599B (en)	2000-11-28	2010-07-21	Medimmune Llc	Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
US7179900B2 (en) *	2000-11-28	2007-02-20	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en)	2000-11-28	2005-02-15	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6989247B2 (en)	2000-11-28	2006-01-24	Celltech R & D, Inc.	Compositions and methods for diagnosing or treating psoriasis
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
DK1355919T3 (da)	2000-12-12	2011-03-14	Medimmune Llc	Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
GEP20084484B (en)	2001-01-05	2008-09-25	Pfizer	Antibodies to insulin-like growth factor i receptor
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20020147312A1 (en) *	2001-02-02	2002-10-10	O'keefe Theresa	Hybrid antibodies and uses thereof
JP2005503116A (ja)	2001-02-09	2005-02-03	ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド	ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
ATE400030T1 (de)	2001-02-19	2008-07-15	Merck Patent Gmbh	Methode zur identifizierung von t-zellepitopen und deren anwendung zur herstellung von molekülen mit reduzierter immunogenität
DK1411962T3 (da)	2001-03-15	2011-04-04	Neogenix Oncology Inc	Terapi for pancreacancer med monoklonalt stof
US8231878B2 (en)	2001-03-20	2012-07-31	Cosmo Research & Development S.P.A.	Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en)	2001-03-20	2015-03-17	Novo Nordisk A/S	Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
DK1385864T3 (da)	2001-04-13	2010-08-16	Human Genome Sciences Inc	Anti-VEGF-2-antistoffer
US7348003B2 (en)	2001-05-25	2008-03-25	Human Genome Sciences, Inc.	Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en)	2001-05-25	2008-04-22	Human Genome Sciences, Inc.	Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
DK1572874T3 (da)	2001-05-25	2013-12-16	Human Genome Sciences Inc	Antistoffer, der immunospecifikt binder til TRAIL receptorer
CA2385745C (en)	2001-06-08	2015-02-17	Abbott Laboratories (Bermuda) Ltd.	Methods of administering anti-tnf.alpha. antibodies
US6867189B2 (en)	2001-07-26	2005-03-15	Genset S.A.	Use of adipsin/complement factor D in the treatment of metabolic related disorders
TWI334439B (en)	2001-08-01	2010-12-11	Centocor Inc	Anti-tnf antibodies, compositions, methods and uses
WO2003014162A1 (en) *	2001-08-03	2003-02-20	Medical & Biological Laboratories Co., Ltd.	ANTIBODY RECOGNIZING GM1 GANGLIOSIDE-BOUND AMYLOID β-PROTEIN AND DNA ENCODING THE ANTIBODY
AU2002329775C1 (en)	2001-08-17	2011-04-07	Eli Lilly And Company	Assay method for alzheimer's disease
US8129504B2 (en)	2001-08-30	2012-03-06	Biorexis Technology, Inc.	Oral delivery of modified transferrin fusion proteins
DE60238497D1 (de) *	2001-09-14	2011-01-13	Fraunhofer Ges Forschung	Immunglobulin mit einem bestimmten rahmengerüst und verfahren zu dessen herstellung und verwendung
GB0124317D0 (en)	2001-10-10	2001-11-28	Celltech R&D Ltd	Biological products
AU2002335808B2 (en) *	2001-10-15	2009-08-27	Ibc Pharmaceuticals	Affinity enhancement agents
EP1441766B1 (en) *	2001-10-16	2011-09-14	MacroGenics West, Inc.	Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof
US20040151721A1 (en)	2001-10-19	2004-08-05	O'keefe Theresa	Humanized anti-CCR2 antibodies and methods of use therefor
WO2003063768A2 (en) *	2001-10-25	2003-08-07	Euro-Celtique S.A.	Compositions and methods directed to anthrax toxin
EP1466177A4 (en) *	2001-12-03	2005-08-17	Abgenix Inc	DISCOVERY OF THERAPEUTIC PRODUCTS
US7754433B2 (en) *	2001-12-03	2010-07-13	Amgen Fremont Inc.	Identification of high affinity molecules by limited dilution screening
EP1461423B1 (en)	2001-12-03	2008-05-14	Amgen Fremont Inc.	Antibody categorization based on binding characteristics
GB0129105D0 (en)	2001-12-05	2002-01-23	Celltech R&D Ltd	Expression control using variable intergenic sequences
ES2545090T3 (es)	2001-12-21	2015-09-08	Human Genome Sciences, Inc.	Proteínas de fusión de albúmina y GCSF
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
CA2481747A1 (en)	2002-04-12	2003-10-23	Medimmune, Inc.	Recombinant anti-interleukin-9 antibodies
US20040009172A1 (en) *	2002-04-26	2004-01-15	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
CA2484121A1 (en)	2002-05-01	2003-11-13	Human Genome Sciences, Inc.	Antibodies that specifically bind to chemokine beta-4
ES2593304T3 (es)	2002-05-02	2016-12-07	Wyeth Holdings Llc	Conjugados de transportador derivado de caliqueamicina
GB0210121D0 (en) *	2002-05-02	2002-06-12	Celltech R&D Ltd	Biological products
AU2012244218C1 (en) *	2002-05-02	2016-12-15	Wyeth Holdings Llc.	Calicheamicin derivative-carrier conjugates
IL149820A0 (en)	2002-05-23	2002-11-10	Curetech Ltd	Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ES2370710T3 (es)	2002-05-28	2011-12-22	Ucb Pharma, S.A.	ISÓMERO POSICIONAL DE PEG DE UN ANTICUERPO ANTI-TNFalfa (CDP870).
EP2070949B1 (en)	2002-06-10	2013-01-16	Vaccinex, Inc.	C35 antibodies and their use in the treatment of cancer
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
EP1551453A4 (en)	2002-06-17	2007-04-25	Us Gov Health & Human Serv	SPECIFICITY GRAFTING OF A MICE RESPONSE TO A HUMAN FRAME
US9321832B2 (en)	2002-06-28	2016-04-26	Domantis Limited	Ligand
CN1678625A (zh)	2002-07-01	2005-10-05	比奥根艾迪克Ma公司	人源化抗淋巴毒素β受体的抗体
SI1944322T1 (sl) *	2002-07-19	2015-06-30	Abbvie Biotechnology Ltd.	Zdravljenje s TNP alfa povezanih bolezni
WO2004016750A2 (en)	2002-08-14	2004-02-26	Macrogenics, Inc.	FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
US8071321B2 (en)	2002-08-29	2011-12-06	Cytocure Llc	Methods for up-regulating antigen expression in tumors
KR20050065587A (ko)	2002-10-08	2005-06-29	이뮤노메딕스, 인코오포레이티드	항체 치료법
LT2891666T (lt)	2002-10-16	2017-10-10	Purdue Pharma L.P.	Antikūnai, kurie prisiriša su ląstelėmis susijusį ca 125/o722p ir jų naudojimo būdas
MY150740A (en) *	2002-10-24	2014-02-28	Abbvie Biotechnology Ltd	Low dose methods for treating disorders in which tnf? activity is detrimental
WO2004110345A2 (en) *	2002-10-29	2004-12-23	Pharmacia Corporation	Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
WO2004039845A1 (en) *	2002-10-31	2004-05-13	Universita'degli Studi Di Roma 'la Sapienza'	Antimicrobial lipase antibodies their nucleotide and aminoacid sequences and uses thereof
EP1900753B1 (en)	2002-11-08	2017-08-09	Ablynx N.V.	Method of administering therapeutic polypeptides, and polypeptides therefor
EP1581096A4 (en) *	2002-11-13	2006-06-21	Raven Biotechnologies Inc	ANTIGEN PIPA AND BINDING ANTIBODIES THEREOF
ATE481422T1 (de)	2002-11-21	2010-10-15	Celltech R & D Inc	Modulieren von immunantworten
CA2507099C (en)	2002-11-26	2013-09-24	Protein Design Labs, Inc.	Chimeric and humanized antibodies to .alpha.5.beta.1 integrin that modulate angiogenesis
ES2388280T3 (es)	2002-12-20	2012-10-11	Abbott Biotherapeutics Corp.	Anticuerpos que reaccionan frente a GPR64 y utilización de los mismos
WO2004063351A2 (en)	2003-01-09	2004-07-29	Macrogenics, Inc.	IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
JP2006518997A (ja)	2003-01-21	2006-08-24	ブリストル−マイヤーズ　スクイブ　カンパニー	新規アシルコエンザイムａ：モノアシルグリセロールアシルトランスフェラーゼ−３（ｍｇａｔ３）をコードするポリヌクレオチドおよびその用途
CA2513113A1 (en) *	2003-01-23	2004-08-05	Genentech, Inc.	Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1594969B1 (en) *	2003-02-01	2015-05-20	Janssen Sciences Ireland UC	Active immunization to generate antibodies to soluble a-beta
US7575747B2 (en) *	2003-02-10	2009-08-18	Applied Molecular Evolution	Aβ binding molecules
GB0303337D0 (en)	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
JP2006522022A (ja)	2003-02-14	2006-09-28	ザキュレイターズオブザユニバーシティーオブミズーリ	プロテアソーム干渉に関連する避妊法および組成物
EP2100619B1 (en)	2003-02-20	2014-02-12	Seattle Genetics, Inc.	Anti-CD70 antibody-drug conjugates and their use for the treatment of immune disorders
PL2248899T3 (pl)	2003-03-19	2015-10-30	Biogen Ma Inc	Białko wiążące receptor nogo
EP1460088A1 (en)	2003-03-21	2004-09-22	Biotest AG	Humanized anti-CD4 antibody with immunosuppressive properties
EP1613273B1 (en)	2003-04-11	2012-06-13	MedImmune, LLC	Recombinant il-9 antibodies and uses thereof
PL1631312T3 (pl)	2003-04-23	2009-02-27	Squibb & Sons Llc	Kompozycje i sposoby terapii choroby zapalenia jelit
US9708410B2 (en)	2003-05-30	2017-07-18	Janssen Biotech, Inc.	Anti-tissue factor antibodies and compositions
US7605235B2 (en)	2003-05-30	2009-10-20	Centocor, Inc.	Anti-tissue factor antibodies and compositions
PE20050627A1 (es)	2003-05-30	2005-08-10	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido beta amiloideo
GB0312481D0 (en)	2003-05-30	2003-07-09	Celltech R&D Ltd	Antibodies
CA2522586C (en)	2003-05-31	2017-02-21	Micromet Ag	Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
AU2004262640B2 (en)	2003-06-16	2010-12-23	Ucb Manufacturing, Inc.	Antibodies specific for sclerostin and methods for increasing bone mineralization
NZ544924A (en)	2003-06-27	2009-03-31	Biogen Idec Inc	Modified binding molecules comprising connecting peptides
JP2008500005A (ja)	2003-07-15	2008-01-10	バロスリサーチインスティテュート	癌及び感染症の免疫療法のための組成物及び方法
ES2523837T3 (es) *	2003-07-18	2014-12-01	Amgen Inc.	Agentes de unión específica al factor de crecimiento de hepatocitos
US7834155B2 (en)	2003-07-21	2010-11-16	Immunogen Inc.	CA6 antigen-specific cytotoxic conjugate and methods of using the same
DK1660513T5 (da) *	2003-07-21	2011-07-18	Immunogen Inc	CA6 antigen-specifikt, cytotoksisk konjugat og fremgangsmåder til anvendelse heraf
US7727752B2 (en)	2003-07-29	2010-06-01	Life Technologies Corporation	Kinase and phosphatase assays
EP1668111A4 (en)	2003-08-08	2008-07-02	Genenews Inc	OSTEOARTHRITIS BIOMARKERS AND USES THEREOF
EA200600234A1 (ru)	2003-08-13	2006-08-25	Пфайзер Продактс Инк.	Модифицированные igf - 1r антитела человека
US20060228350A1 (en) *	2003-08-18	2006-10-12	Medimmune, Inc.	Framework-shuffling of antibodies
US20050048617A1 (en) *	2003-08-18	2005-03-03	Medimmune, Inc.	Humanization of antibodies
US20050042664A1 (en) *	2003-08-22	2005-02-24	Medimmune, Inc.	Humanization of antibodies
GB0321100D0 (en)	2003-09-09	2003-10-08	Celltech R&D Ltd	Biological products
ES2358427T3 (es) *	2003-10-16	2011-05-10	Micromet Ag	Elementos de unión a cd-3 desinmunizados multiespecíficos.
PT1678314E (pt)	2003-10-22	2012-11-27	Keck Graduate Inst	Métodos de síntese de polipéptidos heteromultiméricos em levedura utilizando uma estratégia de conjugação haplóide
EP1687338B1 (en)	2003-11-07	2010-10-20	Ablynx N.V.	Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses thereof
WO2005054868A1 (en) *	2003-12-05	2005-06-16	Multimmune Gmbh	Compositions and methods for the treatment and diagnosis of neoplastic and infectious diseases
CA2551110C (en)	2003-12-23	2016-01-19	Tanox, Inc.	Treatment of cancer with novel anti-il 13 monoclonal antibodies
WO2005068503A2 (en)	2004-01-07	2005-07-28	Chiron Corporation	M-csf-specific monoclonal antibody and uses thereof
US20070280950A1 (en)	2004-01-19	2007-12-06	Medical And Biological Laboratories Co., Ltd.	Inflammatory Cytokine Inhibitors
BRPI0507026A (pt)	2004-02-09	2007-04-17	Human Genome Sciences Inc	proteìnas de fusão de albumina
EP2340850A1 (en)	2004-02-10	2011-07-06	The Regents of the University of Colorado, a Body Corporate	Inhibition of factor B, the alternative complement pathway and methods related thereto
EP1756162A1 (en)	2004-03-23	2007-02-28	Biogen Idec MA Inc.	Receptor coupling agents and therapeutic uses thereof
WO2005097184A2 (en)	2004-03-26	2005-10-20	Human Genome Sciences, Inc.	Antibodies against nogo receptor
JP5128935B2 (ja)	2004-03-31	2013-01-23	ジェネンテック，インコーポレイテッド	ヒト化抗ＴＧＦ−β抗体
TW201705980A (zh)	2004-04-09	2017-02-16	艾伯維生物技術有限責任公司	用於治療ＴＮＦα相關失調症之多重可變劑量療法
US9228008B2 (en)	2004-05-28	2016-01-05	Idexx Laboratories, Inc.	Canine anti-CD20 antibodies
CN101001878B (zh)	2004-06-21	2012-09-26	米德列斯公司	干扰素α受体1抗体及其用途
ES2395094T3 (es)	2004-06-24	2013-02-08	Biogen Idec Ma Inc.	Tratamiento de afecciones que implican la desmielinización
US20060019342A1 (en) *	2004-06-25	2006-01-26	Medimmune, Inc.	Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
GB0414886D0 (en)	2004-07-02	2004-08-04	Neutec Pharma Plc	Treatment of bacterial infections
EP1802341A1 (en)	2004-07-16	2007-07-04	Pfizer Products Inc.	Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
DK1781321T3 (da) *	2004-08-02	2014-04-14	Zenyth Operations Pty Ltd	Fremgangsmåde til behandling af cancer, der omfatter en vegf-b-antagonist
EP1789070B1 (en)	2004-08-03	2012-10-24	Biogen Idec MA Inc.	Taj in neuronal function
EP2319925B1 (en)	2004-08-16	2018-07-25	Quark Pharmaceuticals, Inc.	Therapeutic uses of inhibitors of RTP801
CA2486285C (en)	2004-08-30	2017-03-07	Viktor S. Goldmakher	Immunoconjugates targeting syndecan-1 expressing cells and use thereof
AU2005286770A1 (en)	2004-09-21	2006-03-30	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2006041970A2 (en) *	2004-10-08	2006-04-20	Abbott Biotechnology Ltd.	Treatment of respiratory syncytial virus (rsv) infection
AU2005299355A1 (en)	2004-10-27	2006-05-04	Medimmune, Llc	Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1812068A4 (en) *	2004-10-29	2010-06-09	Medimmune Inc	METHODS FOR PREVENTING AND TREATING RSV INFECTIONS AND ASSOCIATED DISEASES
GB0426146D0 (en)	2004-11-29	2004-12-29	Bioxell Spa	Therapeutic peptides and method
JP4881874B2 (ja)	2004-12-06	2012-02-22	協和発酵キリン株式会社	インフルエンザｍ２タンパク質に対するヒトモノクローナル抗体及びその生産方法及びその使用
ES2434732T3 (es)	2004-12-15	2013-12-17	Janssen Alzheimer Immunotherapy	Anticuerpos para beta-amiloide humanizados para su uso en mejorar la cognición
ES2396555T3 (es)	2004-12-15	2013-02-22	Janssen Alzheimer Immunotherapy	Anticuerpos que reconocen péptido beta amiloide
US20060257396A1 (en) *	2004-12-15	2006-11-16	Jacobsen Jack S	Abeta antibodies for use in improving cognition
WO2006074399A2 (en)	2005-01-05	2006-07-13	Biogen Idec Ma Inc.	Multispecific binding molecules comprising connecting peptides
EP2446897A1 (en)	2005-01-06	2012-05-02	Novo Nordisk A/S	Anti-KIR combination treatments and methods
CA2599589A1 (en)	2005-02-07	2006-08-17	Genenews,Inc.	Mild osteoarthritis biomarkers and uses thereof
EP1853718B1 (en)	2005-02-15	2015-08-05	Duke University	Anti-cd19 antibodies and uses in oncology
EP1858545A2 (en)	2005-03-04	2007-11-28	Curedm Inc.	Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
CA2602035C (en)	2005-03-18	2015-06-16	Medimmune, Inc.	Framework-shuffling of antibodies
JP2008532559A (ja)	2005-03-19	2008-08-21	メディカルリサーチカウンシル	ウイルス感染の治療及び予防又は治療及び予防の改善
EP3153525A1 (en)	2005-03-23	2017-04-12	Genmab A/S	Antibodies against cd38 for treatment of multiple myeloma
US9889197B2 (en)	2005-04-15	2018-02-13	Macrogenics, Inc.	Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
ES2971647T3 (es)	2005-04-15	2024-06-06	Macrogenics Inc	Diacuerpos covalentes y usos de los mismos
CN101203241B (zh)	2005-04-19	2012-02-22	西雅图基因公司	人源化抗-cd70结合物和其应用
US20090041783A1 (en)	2005-04-28	2009-02-12	Mochida Pharmaceutical Co., Ltd.	Anti-platelet membrane glycoprotein vi monoclonal antibody
WO2006121852A2 (en)	2005-05-05	2006-11-16	Duke University	Anti-cd19 antibody therapy for autoimmune disease
BRPI0611069A2 (pt)	2005-05-06	2010-11-09	Zymogenetics Inc	anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
WO2006121159A1 (ja) *	2005-05-12	2006-11-16	Kyowa Hakko Kogyo Co., Ltd.	Cd10に特異的に反応するヒト型cdr移植抗体およびその抗体断片
CN101500607B (zh)	2005-05-16	2013-11-27	阿布维生物技术有限公司	TNFα抑制剂治疗腐蚀性多关节炎的用途
RU2464276C2 (ru)	2005-05-18	2012-10-20	Аблинкс Н.В.	Улучшенные нанотела против фактора некроза опухоли-альфа
AU2006249087B2 (en)	2005-05-20	2012-05-17	Lonza Biologics Plc	High-level expression of recombinant antibody in a mammalian host cell
CA2608873C (en)	2005-05-20	2017-04-25	Ablynx Nv	Single domain vhh antibodies against von willebrand factor
US7393919B2 (en)	2005-05-25	2008-07-01	Cure Dm, Inc.	Peptides, derivatives and analogs thereof, and methods of using same
BRPI0618160A2 (pt)	2005-05-26	2011-08-16	Univ Colorado	inibição da via alternativa complemento para tratamento de danos cerebrais traumáticos, danos na medula espinhal e condições relacionadas
DK2390267T3 (da) *	2005-06-07	2013-08-26	Esbatech A Novartis Co Llc	Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
JP2008546805A (ja)	2005-06-23	2008-12-25	メディミューン，エルエルシー	最適な凝集および断片化プロフィールを有する抗体製剤
EP1907421A4 (en)	2005-06-30	2012-03-28	Abbott Lab	IL-12 / P40 BINDING PROTEINS
WO2007008604A2 (en)	2005-07-08	2007-01-18	Bristol-Myers Squibb Company	Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
CN101495509B (zh)	2005-07-08	2015-04-22	比奥根艾迪克Ma公司	Sp35抗体及其用途
SG163615A1 (en)	2005-07-11	2010-08-30	Macrogenics Inc	Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
CA2616395C (en)	2005-07-25	2016-10-04	Trubion Pharmaceuticals	B-cell reduction using cd37-specific and cd20-specific binding molecules
EP2311876A3 (en)	2005-07-28	2011-04-27	Novartis AG	M-CSF-specific monoclonal antibody and uses thereof
EP2573114B1 (en)	2005-08-10	2016-03-30	MacroGenics, Inc.	Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2500353A3 (en)	2005-08-19	2012-10-10	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
SG2014010029A (en)	2005-08-19	2014-08-28	Abbott Lab	Dual variable domain immunoglobin and uses thereof
US20070041905A1 (en) *	2005-08-19	2007-02-22	Hoffman Rebecca S	Method of treating depression using a TNF-alpha antibody
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
ES2400520T3 (es)	2005-09-29	2013-04-10	Eisai R&D Management Co., Ltd.	Molécula de adhesión a las células T y anticuerpo contra la molécula
CN101277974A (zh)	2005-09-30	2008-10-01	阿伯特有限及两合公司	排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
DK1940881T3 (en)	2005-10-11	2017-02-20	Amgen Res (Munich) Gmbh	COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
CN101370946B (zh)	2005-10-21	2011-07-20	基因信息股份有限公司	用于使生物标志产物水平与疾病相关联的方法和装置
CA2628451A1 (en)	2005-11-04	2007-05-18	Biogen Idec Ma Inc.	Methods for promoting neurite outgrowth and survival of dopaminergic neurons
MX360959B (es)	2005-11-04	2018-11-23	Genentech Inc	Uso de inhibidores de la vía del complemento para tratar enfermedades oculares.
US20100028358A1 (en)	2005-11-07	2010-02-04	Wolfram Ruf	Compositions and Methods for Controlling Tissue Factor Signaling Specificity
TWI461436B (zh)	2005-11-25	2014-11-21	Kyowa Hakko Kirin Co Ltd	人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
BRPI0619249A2 (pt)	2005-11-30	2011-09-20	Abbott Lab	anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
ES2453941T5 (es)	2005-11-30	2017-05-31	Abbvie Inc.	Anticuerpos monoclonales contra la proteína beta amiloide y usos de los mismos
WO2007064882A2 (en)	2005-12-02	2007-06-07	Biogen Idec Ma Inc.	Treatment of conditions involving demyelination
SI1960430T1 (sl)	2005-12-09	2015-01-30	Ucb Pharma, S.A.	Molekule protiteles s specifiäśnostjo za äśloveĺ ki il-6
GB0525214D0 (en)	2005-12-12	2006-01-18	Bioinvent Int Ab	Biological materials and uses thereof
AU2006328886C1 (en)	2005-12-21	2011-11-17	Amgen Research (Munich) Gmbh	Pharmaceutical compositions with resistance to soluble CEA
AU2007207341B2 (en)	2006-01-20	2012-05-10	Women's & Children's Health Research Institute Incorporated	Method of treatment, prophylaxis and diagnosis of pathologies of the bone
NL2000439C2 (nl)	2006-01-20	2009-03-16	Quark Biotech	Therapeutische toepassingen van inhibitoren van RTP801.
ES2550099T3 (es)	2006-01-27	2015-11-04	Biogen Ma Inc.	Antagonistas del receptor Nogo
WO2007103469A2 (en)	2006-03-06	2007-09-13	Aeres Biomedical Ltd.	Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
BRPI0708771B8 (pt)	2006-03-10	2021-05-25	Wyeth Corp	anticorpos anti-5t4, conjugado de fármaco/ anticorpo para liberação de fármaco, usos dos mesmos e ácido nucléico isolado codificando uma região variável de cadeias pesada e leve anti-5t4
WO2007110631A1 (en)	2006-03-27	2007-10-04	Medimmune Limited	Binding member for gm-csf receptor
US7863426B2 (en)	2006-04-05	2011-01-04	Abbott Biotechnology Ltd.	Antibody purification
EP2004231A4 (en)	2006-04-07	2013-07-10	Nektar Therapeutics	CONJUGATES OF ANTI-TNF-ALPHA ANTIBODY
US20090317399A1 (en) *	2006-04-10	2009-12-24	Pollack Paul F	Uses and compositions for treatment of CROHN'S disease
US9605064B2 (en)	2006-04-10	2017-03-28	Abbvie Biotechnology Ltd	Methods and compositions for treatment of skin disorders
EP2010214A4 (en)	2006-04-10	2010-06-16	Abbott Biotech Ltd	USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
US9624295B2 (en)	2006-04-10	2017-04-18	Abbvie Biotechnology Ltd.	Uses and compositions for treatment of psoriatic arthritis
US20080118496A1 (en) *	2006-04-10	2008-05-22	Medich John R	Uses and compositions for treatment of juvenile rheumatoid arthritis
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
US20080131374A1 (en) *	2006-04-19	2008-06-05	Medich John R	Uses and compositions for treatment of rheumatoid arthritis
US8377448B2 (en)	2006-05-15	2013-02-19	The Board Of Trustees Of The Leland Standford Junior University	CD47 related compositions and methods for treating immunological diseases and disorders
CA2653387A1 (en) *	2006-06-06	2007-12-21	Tolerrx, Inc.	Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
AT503690A1 (de)	2006-06-09	2007-12-15	Biomay Ag	Hypoallergene moleküle
EP2037961B1 (en)	2006-06-14	2015-11-11	MacroGenics, Inc.	Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
LT2029173T (lt) *	2006-06-26	2016-11-10	Macrogenics, Inc.	Fc riib specifiniai antikūnai ir jų panaudojimo būdai
CA2656224C (en)	2006-06-26	2018-01-09	Macrogenics, Inc.	Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
CA2655623C (en)	2006-06-30	2017-12-12	Petrus Johannes Louis Spee	Anti-nkg2a antibodies and uses thereof
KR101440795B1 (ko)	2006-06-30	2014-09-22	애브비 바이오테크놀로지 리미티드	자동 주사 장치
GB0613209D0 (en) *	2006-07-03	2006-08-09	Ucb Sa	Methods
MX2009000709A (es)	2006-07-18	2009-02-04	Sanofi Aventis	Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
JP5102833B2 (ja)	2006-07-24	2012-12-19	バイオレクシスファーマシューティカルコーポレーション	エキセンディン融合タンパク質
GB0614780D0 (en)	2006-07-25	2006-09-06	Ucb Sa	Biological products
CN101626783A (zh)	2006-08-04	2010-01-13	诺华有限公司	Ephb3-特异性抗体和其应用
TW200817438A (en)	2006-08-17	2008-04-16	Hoffmann La Roche	A conjugate of an antibody against CCR5 and an antifusogenic peptide
PT2059535E (pt)	2006-08-18	2014-01-29	Novartis Ag	Anticorpos específicos do prlr e suas utulizações
MX2009002151A (es)	2006-08-28	2009-07-03	Kirin Pharma Kk	Anticuerpos monoclonales humanos especificos para light humano antagonistas.
ES2548714T3 (es)	2006-09-01	2015-10-20	Zymogenetics, Inc.	Anticuerpos monoclonales IL-31 y procedimientos de uso
SMT202000607T1 (it)	2006-09-08	2021-01-05	Abbvie Bahamas Ltd	Proteine leganti l'interleuchina-13
AU2007313300A1 (en)	2006-10-16	2008-04-24	Medimmune, Llc.	Molecules with reduced half-lives, compositions and uses thereof
GB0620729D0 (en)	2006-10-18	2006-11-29	Ucb Sa	Biological products
EP1914242A1 (en)	2006-10-19	2008-04-23	Sanofi-Aventis	Novel anti-CD38 antibodies for the treatment of cancer
CN101626785A (zh)	2006-11-17	2010-01-13	财团法人阪大微生物病研究会	神经延长促进剂及延长抑制剂
US8785400B2 (en)	2006-11-22	2014-07-22	Curedm Group Holdings, Llc	Methods and compositions relating to islet cell neogenesis
EP2431053A1 (en)	2006-11-27	2012-03-21	Patrys Limited	Novel glycosylated peptide target in neoplastic cells
TW200831528A (en)	2006-11-30	2008-08-01	Astrazeneca Ab	Compounds
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
ES2523915T5 (es)	2006-12-01	2022-05-26	Seagen Inc	Agentes de unión a la diana variantes y usos de los mismos
CN101678100A (zh)	2006-12-06	2010-03-24	米迪缪尼有限公司	治疗系统性红斑狼疮的方法
BRPI0720437A2 (pt)	2006-12-07	2014-01-07	Novartis Ag	Anticorpos antafonísticos contra ephb3
EP2505651A3 (en)	2006-12-10	2013-01-09	Dyadic International, Inc.	Isolated fungus with reduced protease activity
MX2009006500A (es)	2006-12-18	2009-06-26	Genentech Inc	Anticuerpos antagonistas anti-notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3.
AU2007336243B2 (en)	2006-12-19	2012-07-26	Ablynx N.V.	Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
EP2115004A2 (en)	2006-12-19	2009-11-11	Ablynx N.V.	Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
PL2740744T3 (pl)	2007-01-09	2019-01-31	Biogen Ma Inc.	Przeciwciała przeciw białku sp35 i ich zastosowania
US8128926B2 (en)	2007-01-09	2012-03-06	Biogen Idec Ma Inc.	Sp35 antibodies and uses thereof
ES2825718T3 (es)	2007-02-01	2021-05-17	Univ Der Johannes Gutenberg Univ Mainz	Activación específica de una célula T reguladora y su uso para el tratamiento del asma, enfermedades alérgicas, enfermedades autoinmunes, rechazo de injertos y para la inducción de tolerancia
WO2008098139A2 (en)	2007-02-07	2008-08-14	The Regents Of The University Of Colorado	Axl tyrosine kinase inhibitors and methods of making and using the same
EP1958645A1 (en)	2007-02-13	2008-08-20	Biomay AG	Peptides derived from the major allergen of ragweed (Ambrosia artemisiifolia) and uses thereof
AR065368A1 (es)	2007-02-15	2009-06-03	Astrazeneca Ab	Anticuerpos para moleculas de ige
US8685666B2 (en)	2007-02-16	2014-04-01	The Board Of Trustees Of Southern Illinois University	ARL-1 specific antibodies and uses thereof
US8114606B2 (en)	2007-02-16	2012-02-14	The Board Of Trustees Of Southern Illinois University	ARL-1 specific antibodies
US9023352B2 (en)	2007-02-20	2015-05-05	Tufts University	Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
WO2008104386A2 (en)	2007-02-27	2008-09-04	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
TW200902544A (en)	2007-03-13	2009-01-16	Hoffmann La Roche	Peptide-complement conjugates
ES2713859T3 (es)	2007-03-22	2019-05-24	Biogen Ma Inc	Proteínas de unión, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen específicamente a CD154 y usos de los mismos
US8557588B2 (en) *	2007-03-27	2013-10-15	Schlumberger Technology Corporation	Methods and apparatus for sampling and diluting concentrated emulsions
CA2682170A1 (en)	2007-03-30	2008-10-09	Medimmune, Llc	Antibodies with decreased deamidation profiles
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
ES2540807T3 (es)	2007-05-04	2015-07-13	Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa	Dominios variables de anticuerpos de conejo modificados por ingeniería genética y usos de los mismos
ES2558689T3 (es)	2007-05-14	2016-02-08	Medimmune, Llc	Métodos para reducir los niveles de eosinófilos
EP2158215B1 (en)	2007-05-17	2015-04-22	Genentech, Inc.	Crystal structures of neuropilin fragments and neuropilin-antibody complexes
US8062864B2 (en)	2007-05-21	2011-11-22	Alderbio Holdings Llc	Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US9701747B2 (en)	2007-05-21	2017-07-11	Alderbio Holdings Llc	Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
SG183742A1 (en)	2007-05-21	2012-09-27	Alderbio Holdings Llc	Antibodies to il-6 and use thereof
US8178101B2 (en)	2007-05-21	2012-05-15	Alderbio Holdings Inc.	Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US7906117B2 (en)	2007-05-21	2011-03-15	Alderbio Holdings Llc	Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
AU2008254578B2 (en) *	2007-05-21	2013-06-06	Alderbio Holdings Llc	Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8252286B2 (en)	2007-05-21	2012-08-28	Alderbio Holdings Llc	Antagonists of IL-6 to prevent or treat thrombosis
US8404235B2 (en)	2007-05-21	2013-03-26	Alderbio Holdings Llc	Antagonists of IL-6 to raise albumin and/or lower CRP
EP1997830A1 (en) *	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
WO2008154543A2 (en)	2007-06-11	2008-12-18	Abbott Biotechnology Ltd.	Methods for treating juvenile idiopathic arthritis
US8048420B2 (en)	2007-06-12	2011-11-01	Ac Immune S.A.	Monoclonal antibody
US8613923B2 (en)	2007-06-12	2013-12-24	Ac Immune S.A.	Monoclonal antibody
MX2009013816A (es)	2007-06-21	2010-02-24	Macrogenics Inc	Diacuerpos covalentes y usos de los mismos.
GB0712503D0 (en)	2007-06-27	2007-08-08	Therapeutics Pentraxin Ltd	Use
US20090022720A1 (en)	2007-07-20	2009-01-22	Stephan Fischer	Conjugate of an antibody against CD4 and antifusogenic peptides
PT2182983E (pt)	2007-07-27	2014-09-01	Janssen Alzheimer Immunotherap	Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
US8551751B2 (en)	2007-09-07	2013-10-08	Dyadic International, Inc.	BX11 enzymes having xylosidase activity
US8647622B2 (en)	2007-08-29	2014-02-11	Sanofi	Humanized anti-CXCR5 antibodies, derivatives thereof and their use
MX337147B (es)	2007-08-30	2016-02-15	Curedm Group Holdings Llc	Composiciones y metodos para utilizar peptidos proislet y sus analogos.
JP5658564B2 (ja) *	2007-08-31	2015-01-28	ザ・ユニバーシティ・オブ・シカゴＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＣｈｉｃａｇｏ	ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
GB0717337D0 (en)	2007-09-06	2007-10-17	Ucb Pharma Sa	Method of treatment
WO2009039310A2 (en)	2007-09-18	2009-03-26	La Jolla Institute For Allergy And Immunology	Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
ES2622460T3 (es)	2007-09-26	2017-07-06	Ucb Biopharma Sprl	Fusiones de anticuerpos con doble especificidad
US9403902B2 (en)	2007-10-05	2016-08-02	Ac Immune S.A.	Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
SG178809A1 (en) *	2007-10-05	2012-03-29	Genentech Inc	Use of anti-amyloid beta antibody in ocular diseases
EP2050764A1 (en)	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
KR20100098620A (ko)	2007-11-05	2010-09-08	메디뮨 엘엘씨	경피증의 치료 방법
US20100266604A1 (en)	2007-11-09	2010-10-21	The Salk Institute For Biological Studies	Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
EP2586797A3 (en)	2007-11-27	2013-07-24	Medtronic, Inc.	Humanized anti-amyloid beta antibodies
JP5490714B2 (ja)	2007-11-28	2014-05-14	メディミューン，エルエルシー	タンパク質製剤
PL2796466T3 (pl)	2007-12-07	2018-04-30	Zymogenetics, Inc.	Humanizowane cząsteczki przeciwciała swoiste dla il-31
BRPI0821658B8 (pt)	2007-12-14	2021-05-25	Novo Nordisk As	anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos
JP5990365B2 (ja)	2007-12-26	2016-09-14	バイオテスト・アクチエンゲゼルシヤフト	Ｃｄ１３８を標的とする剤及びその使用
CN101932333A (zh)	2007-12-26	2010-12-29	瓦西尼斯公司	抗c35抗体联合疗法和方法
RU2486203C2 (ru)	2007-12-26	2013-06-27	Биотест Аг	Способы улучшения направленного воздействия на cd138-экспрессирующие опухолевые клетки и агенты для их осуществления
US9011864B2 (en)	2007-12-26	2015-04-21	Biotest Ag	Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
WO2009080830A1 (en)	2007-12-26	2009-07-02	Biotest Ag	Immunoconjugates targeting cd138 and uses thereof
GB0800277D0 (en)	2008-01-08	2008-02-13	Imagination Tech Ltd	Video motion compensation
EP2388323B1 (en)	2008-01-11	2016-04-13	Gene Techno Science Co., Ltd.	Humanized anti-9 integrin antibodies and the uses thereof
NZ601913A (en)	2008-01-15	2014-02-28	Abbott Gmbh & Co Kg	Powdered protein compositions and methods of making same
AU2009205995B2 (en)	2008-01-18	2014-04-03	Medimmune, Llc	Cysteine engineered antibodies for site-specific conjugation
EP2247619A1 (en)	2008-01-24	2010-11-10	Novo Nordisk A/S	Humanized anti-human nkg2a monoclonal antibody
HUE032025T2 (en)	2008-01-31	2017-08-28	Inserm - Inst Nat De La Sante Et De La Rech Medicale	Antibodies to human CD39 and their use to inhibit regulatory T cell activity
KR101666229B1 (ko)	2008-02-08	2016-10-14	메디뮨 엘엘씨	Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
US8962803B2 (en)	2008-02-29	2015-02-24	AbbVie Deutschland GmbH & Co. KG	Antibodies against the RGM A protein and uses thereof
BRPI0909048A2 (pt)	2008-03-13	2015-11-24	Biotest Ag	composição farmacêutica, e, método de tratamento de uma doença autoimune
MX2010010026A (es)	2008-03-13	2011-03-21	Biotest Ag	Agente para tratar enfermedad.
CA2717812A1 (en)	2008-03-13	2009-09-17	Biotest Ag	Agent for treating disease
EP2260102A1 (en)	2008-03-25	2010-12-15	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by down-regulating frizzled-4 and/or frizzled-1
JPWO2009119794A1 (ja)	2008-03-27	2011-07-28	タカラバイオ株式会社	感染症予防、治療剤
ES2447844T3 (es)	2008-04-03	2014-03-13	Vib Vzw	Anticuerpos de dominio individual capaces de modular la actividad BACE1
US9908943B2 (en)	2008-04-03	2018-03-06	Vib Vzw	Single domain antibodies capable of modulating BACE activity
US8557965B2 (en)	2008-04-07	2013-10-15	Ablynx N.V.	Single variable domains against notch pathway members
KR20110013391A (ko)	2008-04-11	2011-02-09	이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨	Ｃｄ37 면역치료제 및 이작용성 화학치료제와 이의 병용물
GB0807413D0 (en)	2008-04-23	2008-05-28	Ucb Pharma Sa	Biological products
EP2281003B1 (en)	2008-04-24	2017-08-02	Gene Techno Science Co., Ltd.	Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
MX2010011955A (es)	2008-04-29	2011-01-21	Abbott Lab	Inmunoglobulinas de dominio variable doble y usos de las mismas.
CN102076865B (zh)	2008-05-02	2016-03-16	西雅图基因公司	用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
US8323651B2 (en)	2008-05-09	2012-12-04	Abbott Laboratories	Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
US9212226B2 (en)	2008-05-16	2015-12-15	Ablynx N.V.	Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
WO2009148896A2 (en)	2008-05-29	2009-12-10	Nuclea Biotechnologies, LLC	Anti-phospho-akt antibodies
EP2297186B1 (en)	2008-05-29	2018-08-29	The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services,	Expression and assembly of human group c rotavirus-like particles and uses thereof
RU2010153578A (ru)	2008-06-03	2012-07-20	Эбботт Лэборетриз (Us)	Иммуноглобулины с двойными вариабельными доменами и их применение
EP2297209A4 (en)	2008-06-03	2012-08-01	Abbott Lab	IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
WO2010004438A2 (en)	2008-06-16	2010-01-14	Patrys Limited	Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
ES2793008T3 (es)	2008-06-25	2020-11-12	Novartis Ag	Anticuerpos estables y solubles que inhiben VEGF
KR101834797B1 (ko)	2008-06-25	2018-03-07	에스바테크 - 어 노바티스 컴파니 엘엘씨	보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
WO2009155723A2 (en) *	2008-06-25	2009-12-30	Esbatech, An Alcon Biomedical Research Unit Llc	STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
EP2810654A1 (en)	2008-07-08	2014-12-10	AbbVie Inc.	Prostaglandin E2 binding proteins and uses thereof
MX2010014574A (es)	2008-07-08	2011-04-27	Abbott Lab	Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
EP2315779A2 (en)	2008-07-09	2011-05-04	Biogen Idec MA Inc.	Compositions comprising antibodies to lingo or fragments thereof
US8802706B2 (en)	2008-08-07	2014-08-12	Nagasaki University	Method for treating fibromyalgia
NZ591488A (en)	2008-09-07	2012-11-30	Glyconex Inc	Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
WO2010034015A2 (en)	2008-09-22	2010-03-25	The Regents Of The University Of Colorado, A Body Corporate	Modulating the alternative complement pathway
PT2356153T (pt)	2008-10-01	2016-07-15	Amgen Res (Munich) Gmbh	Anticorpo biespecífico, de cadeia única, amepxcd3, específico interespécies
EP3375790A1 (en)	2008-10-01	2018-09-19	Amgen Research (Munich) GmbH	Cross-species-specific single domain bispecific single chain antibody
JP2012504946A (ja)	2008-10-07	2012-03-01	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	血小板第４因子変異体１（ｐｆ４ｖ１）に対する中和抗体およびそのフラグメント
CA2741523C (en)	2008-10-24	2022-06-21	Jonathan S. Towner	Human ebola virus species and compositions and methods thereof
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
US8415291B2 (en)	2008-10-31	2013-04-09	Centocor Ortho Biotech Inc.	Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
US8642280B2 (en)	2008-11-07	2014-02-04	Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Teneurin and cancer
US8298533B2 (en)	2008-11-07	2012-10-30	Medimmune Limited	Antibodies to IL-1R1
US8323649B2 (en)	2008-11-25	2012-12-04	Alderbio Holdings Llc	Antibodies to IL-6 and use thereof
US9212223B2 (en)	2008-11-25	2015-12-15	Alderbio Holdings Llc	Antagonists of IL-6 to prevent or treat thrombosis
US8337847B2 (en)	2008-11-25	2012-12-25	Alderbio Holdings Llc	Methods of treating anemia using anti-IL-6 antibodies
US8992920B2 (en)	2008-11-25	2015-03-31	Alderbio Holdings Llc	Anti-IL-6 antibodies for the treatment of arthritis
US8420089B2 (en)	2008-11-25	2013-04-16	Alderbio Holdings Llc	Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en)	2008-11-25	2016-09-27	Alderbio Holdings Llc	Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
EP2191840A1 (en)	2008-11-28	2010-06-02	Sanofi-Aventis	Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191841A1 (en)	2008-11-28	2010-06-02	Sanofi-Aventis	Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191842A1 (en)	2008-11-28	2010-06-02	Sanofi-Aventis	Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191843A1 (en)	2008-11-28	2010-06-02	Sanofi-Aventis	Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
EP2198884A1 (en)	2008-12-18	2010-06-23	Centre National de la Recherche Scientifique (CNRS)	Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5
ES2733067T3 (es)	2008-12-19	2019-11-27	Macrogenics Inc	Diacuerpos covalentes y usos de los mismos
AU2009334498A1 (en)	2008-12-31	2011-07-21	Biogen Idec Ma Inc.	Anti-lymphotoxin antibodies
GB0900425D0 (en)	2009-01-12	2009-02-11	Ucb Pharma Sa	Biological products
CA2749572A1 (en)	2009-01-14	2010-07-22	Iq Therapeutics Bv	Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
KR101245929B1 (ko)	2009-01-20	2013-03-22	호메이욘 에이치. 자데흐	항체 매개된 골질 재생
CA2749966A1 (en)	2009-01-29	2010-08-05	Abbott Laboratories	Il-1 binding proteins
WO2010087927A2 (en)	2009-02-02	2010-08-05	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP2396035A4 (en)	2009-02-12	2012-09-12	Human Genome Sciences Inc	USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
ES2712732T3 (es)	2009-02-17	2019-05-14	Cornell Res Foundation Inc	Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
EP2398498B1 (en)	2009-02-17	2018-09-05	UCB Biopharma SPRL	Antibody molecules having specificity for human ox40
GB0902916D0 (en)	2009-02-20	2009-04-08	Fusion Antibodies Ltd	Antibody therapy
US8030026B2 (en)	2009-02-24	2011-10-04	Abbott Laboratories	Antibodies to troponin I and methods of use thereof
EP2403531A4 (en)	2009-03-05	2013-02-27	Abbott Lab	IL-17 BINDING PROTEINS
EP2405920A1 (en)	2009-03-06	2012-01-18	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Novel therapy for anxiety
WO2010104208A1 (en)	2009-03-10	2010-09-16	Gene Techno Science Co., Ltd.	Generation, expression and characterization of the humanized k33n monoclonal antibody
GB0904214D0 (en)	2009-03-11	2009-04-22	Ucb Pharma Sa	Biological products
WO2010105290A1 (en) *	2009-03-16	2010-09-23	Cephalon Australia Pty Ltd	Humanised antibodies with anti-tumour activity
EP3002296B1 (en)	2009-03-17	2020-04-29	Université d'Aix-Marseille	Btla antibodies and uses thereof
EP2411412B1 (en)	2009-03-24	2015-05-27	Teva Biopharmaceuticals USA, Inc.	Humanized antibodies against light and uses thereof
US20120070450A1 (en)	2009-03-24	2012-03-22	Riken	Leukemia stem cell markers
SG174862A1 (en)	2009-04-10	2011-11-28	Ablynx Nv	Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorder
ES2571235T3 (es)	2009-04-10	2016-05-24	Kyowa Hakko Kirin Co Ltd	Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
EP2241323A1 (en)	2009-04-14	2010-10-20	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Tenascin-W and brain cancers
AU2010236256C1 (en)	2009-04-16	2015-10-22	Abbvie Biotherapeutics Inc.	Anti-TNF-alpha antibodies and their uses
WO2010126066A1 (ja)	2009-04-27	2010-11-04	協和発酵キリン株式会社	血液腫瘍治療を目的とした抗IL-3Rα抗体
US9309325B2 (en)	2009-05-07	2016-04-12	The Regents Of The University Of California	Antibodies and methods of use thereof
FR2945538B1 (fr)	2009-05-12	2014-12-26	Sanofi Aventis	Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
CN105061592A (zh)	2009-06-05	2015-11-18	埃博灵克斯股份有限公司	用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
EP2440934B1 (en)	2009-06-08	2014-07-16	Vib Vzw	Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation
US8609097B2 (en) *	2009-06-10	2013-12-17	Hoffmann-La Roche Inc.	Use of an anti-Tau pS422 antibody for the treatment of brain diseases
ES2602611T3 (es)	2009-06-15	2017-02-21	Vib Vzw	Anticuerpos inhibidores de BACE1
AU2010262836B2 (en)	2009-06-17	2015-05-28	Abbvie Biotherapeutics Inc.	Anti-VEGF antibodies and their uses
WO2011005481A1 (en)	2009-06-22	2011-01-13	Medimmune, Llc	ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
CA2767105A1 (en)	2009-07-02	2011-01-06	Musc Foundation For Research Development	Methods of stimulating liver regeneration
EA022788B1 (ru)	2009-07-03	2016-03-31	Бионор Иммуно Ас	Новые терапевтические и диагностические средства
JP5762408B2 (ja)	2009-08-13	2015-08-12	クルセルホランドベーヴェー	ヒト呼吸器合胞体ウイルス（ｒｓｖ）に対する抗体および使用方法
ES2666152T3 (es)	2009-08-13	2018-05-03	The Johns Hopkins University	Métodos de modulación de la función inmunitaria con anticuerpos anti-B7-H7CR
EP2292266A1 (en)	2009-08-27	2011-03-09	Novartis Forschungsstiftung, Zweigniederlassung	Treating cancer by modulating copine III
CN102002104A (zh)	2009-08-28	2011-04-06	江苏先声药物研究有限公司	一种抗vegf的单克隆抗体及含有该抗体的药物组合物
MX336152B (es)	2009-08-29	2016-01-08	Abbvie Inc	Proteinas terapeutico de union a dll4.
AU2010286427A1 (en)	2009-08-31	2012-03-08	Abbott Biotherapeutics Corp.	Use of an immunoregulatory NK cell population for monitoring the efficacy of anti-IL-2R antibodies in multiple sclerosis patients
PE20121530A1 (es)	2009-09-01	2012-12-22	Abbvie Inc	Inmunoglobulinas con dominio variable dual
WO2011036118A1 (en)	2009-09-22	2011-03-31	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by modulating mex-3
GB201005063D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
TW201116297A (en)	2009-10-02	2011-05-16	Sanofi Aventis	Antibodies that specifically bind to the EphA2 receptor
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
LT2486141T (lt)	2009-10-07	2018-05-25	Macrogenics, Inc.	Fc regioną turintys polipeptidai, pasižymintys pagerinta efektorine funkcija dėl fukozilinimo laipsnio pasikeitimų, ir jų naudojimo būdai
AU2010306677B2 (en)	2009-10-15	2013-05-23	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
WO2011045352A2 (en)	2009-10-15	2011-04-21	Novartis Forschungsstiftung	Spleen tyrosine kinase and brain cancers
IN2012DN03348A (fi)	2009-10-16	2015-10-23	Biorealites
GB0922435D0 (en)	2009-12-22	2010-02-03	Ucb Pharma Sa	Method
US8734798B2 (en)	2009-10-27	2014-05-27	Ucb Pharma S.A.	Function modifying NAv 1.7 antibodies
GB0922434D0 (en)	2009-12-22	2010-02-03	Ucb Pharma Sa	antibodies and fragments thereof
US9234037B2 (en)	2009-10-27	2016-01-12	Ucb Biopharma Sprl	Method to generate antibodies to ion channels
US8658175B2 (en)	2009-10-28	2014-02-25	Abbvie Biotherapeutics Inc.	Anti-EGFR antibodies and their uses
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
US9273283B2 (en)	2009-10-29	2016-03-01	The Trustees Of Dartmouth College	Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en)	2009-10-29	2011-05-19	Trustees Of Dartmouth College	T cell receptor-deficient t cell compositions
WO2011053777A1 (en)	2009-10-30	2011-05-05	Abbott Biotherapeutics Corp.	Use of immunoregulatory nk cell populations for predicting the efficacy of anti-il-2r antibodies in multiple sclerosis patients
US20120213801A1 (en)	2009-10-30	2012-08-23	Ekaterina Gresko	Phosphorylated Twist1 and cancer
WO2011053707A1 (en)	2009-10-31	2011-05-05	Abbott Laboratories	Antibodies to receptor for advanced glycation end products (rage) and uses thereof
EP2496257A4 (en) *	2009-11-05	2013-02-27	Cephalon Australia Pty Ltd	TREATMENT OF CANCER CHARACTERIZED BY THE MUTATION OF KRAS OR BRAF GENES
WO2011066369A2 (en)	2009-11-24	2011-06-03	Alder Biopharmaceuticals, Inc.	Antagonists of il-6 to raise albumin and/or lower crp
US9775921B2 (en)	2009-11-24	2017-10-03	Alderbio Holdings Llc	Subcutaneously administrable composition containing anti-IL-6 antibody
GB0920944D0 (en)	2009-11-30	2010-01-13	Biotest Ag	Agents for treating disease
CA2782459A1 (en)	2009-12-04	2011-06-09	Katholieke Universiteit Leuven, K.U.Leuven R&D	Arf6 as a new target for treating alzheimer's disease
US9175075B2 (en)	2009-12-08	2015-11-03	AbbVie Deutschland GmbH & Co. KG	Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
EP2513148B1 (en)	2009-12-16	2016-08-31	AbbVie Biotherapeutics Inc.	Anti-her2 antibodies and their uses
CA2785587A1 (en)	2009-12-23	2011-06-30	4-Antibody Ag	Binding members for human cytomegalovirus
US9217032B2 (en)	2010-01-08	2015-12-22	Les Laboratoires Servier	Methods for treating colorectal cancer
US9487582B2 (en)	2010-01-08	2016-11-08	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Methods for treating pancreatic cancer
US8900817B2 (en)	2010-01-08	2014-12-02	Les Laboratories Servier	Progastrin and liver pathologies
GB201001791D0 (en)	2010-02-03	2010-03-24	Ucb Pharma Sa	Process for obtaining antibodies
NZ602734A (en)	2010-03-02	2014-10-31	Abbvie Inc	Therapeutic dll4 binding proteins
US9434716B2 (en)	2011-03-01	2016-09-06	Glaxo Group Limited	Antigen binding proteins
US20130004519A1 (en)	2010-03-05	2013-01-03	Ruth Chiquet-Ehrismann	Smoci, tenascin-c and brain cancers
EP2545078A1 (en)	2010-03-11	2013-01-16	UCB Pharma, S.A.	Pd-1 antibody
TW201134488A (en)	2010-03-11	2011-10-16	Ucb Pharma Sa	PD-1 antibodies
AU2011231978B2 (en)	2010-03-24	2014-12-18	Centre National De La Recherche Scientifique (Cnrs)	Prophylaxis of colorectal and gastrointestinal cancer
GB201005064D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
US10472426B2 (en)	2010-03-25	2019-11-12	Ucb Biopharma Sprl	Disulfide stabilized DVD-Ig molecules
TWI653333B (zh)	2010-04-01	2019-03-11	安進研究（慕尼黑）有限責任公司	跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
WO2011127580A1 (en)	2010-04-14	2011-10-20	National Research Council Of Canada	Compositions and methods for brain delivery of analgesic peptides
EP2558494B1 (en)	2010-04-15	2018-05-23	AbbVie Inc.	Amyloid-beta binding proteins
MX340683B (es)	2010-04-16	2016-07-21	Biogen Ma Inc	Anticuerpos anti-vla-4.
EP2561076A1 (en)	2010-04-19	2013-02-27	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Modulating xrn1
BR122014011544A2 (pt)	2010-05-14	2019-08-13	Abbvie Inc	proteínas de ligação à il-1
WO2011149461A1 (en)	2010-05-27	2011-12-01	Medtronic, Inc.	Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
WO2011154485A1 (en)	2010-06-10	2011-12-15	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by modulating mammalian sterile 20-like kinase 3
WO2011160119A2 (en)	2010-06-19	2011-12-22	Memorial Sloan-Kettering Cancer Center	Anti-gd2 antibodies
JP2013530981A (ja)	2010-06-25	2013-08-01	アストンユニバーシティ	脂質動員特性を有する糖タンパク質およびその治療的使用
US20120009196A1 (en)	2010-07-08	2012-01-12	Abbott Laboratories	Monoclonal antibodies against hepatitis c virus core protein
UY33492A (es)	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
AU2011274472B2 (en)	2010-07-09	2017-03-30	Janssen Vaccines & Prevention B.V.	Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
WO2012010696A1 (en)	2010-07-23	2012-01-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for cancer management targeting co-029
CN103261224B (zh)	2010-07-26	2015-10-07	瑟维尔实验室	用于肝癌治疗的方法和组合物
GB201012599D0 (en)	2010-07-27	2010-09-08	Ucb Pharma Sa	Process for purifying proteins
NZ606357A (en)	2010-07-30	2015-05-29	Genentech Inc	Safe and functional humanized anti beta-amyloid antibody
BR112013002578A2 (pt)	2010-08-03	2019-05-14	Abbvie Inc.	imunoglobinas de domínio variável duplo e usos das mesmas
EP3533803B1 (en)	2010-08-14	2021-10-27	AbbVie Inc.	Anti-amyloid-beta antibodies
SI3333188T1 (sl)	2010-08-19	2022-04-29	Zoetis Belgium S.A.	Protitelesa proti NGF in njihova uporaba
GB201014033D0 (en)	2010-08-20	2010-10-06	Ucb Pharma Sa	Biological products
KR20130139884A (ko)	2010-08-26	2013-12-23	애브비 인코포레이티드	이원 가변 도메인 면역글로불린 및 이의 용도
EP2614080A1 (en)	2010-09-10	2013-07-17	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Phosphorylated twist1 and metastasis
US9066986B2 (en)	2010-10-01	2015-06-30	National Research Council Of Canada	Anti-CEACAM6 antibodies and uses thereof
UY33679A (es)	2010-10-22	2012-03-30	Esbatech	Anticuerpos estables y solubles
WO2012055030A1 (en)	2010-10-25	2012-05-03	National Research Council Of Canada	Clostridium difficile-specific antibodies and uses thereof
DK2634194T3 (en)	2010-10-29	2018-10-01	Perseus Proteomics Inc	ANTI-CDH3 ANTIBODY WITH HIGH INTERNALIZATION CAPACITY
US20140093506A1 (en)	2010-11-15	2014-04-03	Marc Buehler	Anti-fungal-agents
JP2014500879A (ja)	2010-11-16	2014-01-16	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
PE20140633A1 (es)	2010-11-19	2014-05-30	Eisai Randd Man Co Ltd	Anticuerpos neutralizadores anti-ccl20
US9304134B2 (en)	2010-11-23	2016-04-05	Alderbio Holdings Llc	Anti-IL-6 antibodies for the treatment of anemia
US9249217B2 (en)	2010-12-03	2016-02-02	Secretary, DHHS	Bispecific EGFRvIII x CD3 antibody engaging molecules
UA112170C2 (uk)	2010-12-10	2016-08-10	Санофі	Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
WO2012080769A1 (en)	2010-12-15	2012-06-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-cd277 antibodies and uses thereof
JP2014508511A (ja)	2010-12-20	2014-04-10	メドイミューン・リミテッド	抗ｉｌ−１８抗体およびそれらの使用
US20120275996A1 (en)	2010-12-21	2012-11-01	Abbott Laboratories	IL-1 Binding Proteins
PE20141060A1 (es)	2010-12-21	2014-09-26	Abbvie Inc	Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso
WO2012085132A1 (en)	2010-12-22	2012-06-28	Orega Biotech	Antibodies against human cd39 and use thereof
US9505826B2 (en)	2010-12-22	2016-11-29	Teva Pharmaceuticals Australia Pty Ltd	Modified antibody with improved half-life
US20120171195A1 (en)	2011-01-03	2012-07-05	Ravindranath Mepur H	Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
MY162790A (en)	2011-01-14	2017-07-14	Ucb Pharma Sa	Antibody molecules which bind il-17a and il-17f
WO2012101125A1 (en)	2011-01-24	2012-08-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Specific antibodies against human cxcl4 and uses thereof
DK2668210T3 (da)	2011-01-26	2020-08-24	Celldex Therapeutics Inc	Anti-kit antistoffer og anvendelser deraf
WO2012110500A1 (en)	2011-02-15	2012-08-23	Vib Vzw	Means and methods for improvement of synaptic dysfunction disorders
AR085302A1 (es)	2011-02-24	2013-09-18	Sanofi Sa	Metodo de produccion de anticuerpos sialilados
KR101969526B1 (ko)	2011-02-28	2019-04-17	고쿠리츠켄큐카이하츠호진 고쿠리츠쥰칸키뵤 겐큐센터	악성 종양 전이 억제용 의약
WO2012119989A2 (en)	2011-03-04	2012-09-13	Oryzon Genomics, S.A.	Methods and antibodies for the diagnosis and treatment of cancer
WO2012122528A1 (en)	2011-03-10	2012-09-13	Hco Antibody, Inc.	Bispecific three-chain antibody-like molecules
US8722044B2 (en)	2011-03-15	2014-05-13	Janssen Biotech, Inc.	Human tissue factor antibody and uses thereof
PL3235508T3 (pl)	2011-03-16	2021-07-12	Sanofi	Kompozycje zawierające białko podobne do przeciwciała z podwójnym regionem v
EP3147297B1 (en)	2011-03-31	2018-12-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies directed against icos and uses thereof
LT2699264T (lt)	2011-04-20	2018-07-10	Medimmune, Llc	Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1
JP2014518615A (ja)	2011-04-22	2014-08-07	エマージェントプロダクトデベロップメントシアトル，エルエルシー	前立腺特異的膜抗原結合タンパク質および関連組成物ならびに方法
EP2702077A2 (en)	2011-04-27	2014-03-05	AbbVie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
TWI723339B (zh)	2011-05-02	2021-04-01	美商千禧製藥公司	抗-α4β7抗體之調配物
UA116189C2 (uk)	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
ES2643694T3 (es)	2011-05-19	2017-11-23	Inserm (Institut National De La Santé Et De La Recherche Medicale)	Anticuerpos anti-HER3 humanos y sus usos
MX347818B (es)	2011-05-21	2017-05-15	Macrogenics Inc	Dominios que enlazan suero desinmunizados y su uso para prolongar la vida media en suero.
AR086543A1 (es)	2011-05-25	2014-01-08	Bg Medicine Inc	Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
CN108329391A (zh)	2011-05-27	2018-07-27	埃博灵克斯股份有限公司	使用rankl结合肽抑制骨质吸收
WO2012166555A1 (en)	2011-05-27	2012-12-06	Nektar Therapeutics	Water - soluble polymer - linked binding moiety and drug compounds
WO2012168259A1 (en)	2011-06-06	2012-12-13	Novartis Forschungsstiftung, Zweigniederlassung	Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
WO2012170742A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en)	2011-06-07	2016-01-26	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
US9309305B2 (en)	2011-06-10	2016-04-12	National Research Council Of Canada	Anti-ricin antibodies and uses thereof
RU2708977C2 (ru)	2011-06-10	2019-12-12	МЕДИММЬЮН, ЭлЭлСи	Молекулы, связывающиеся с psl pseudomonas, и пути их применения
KR20140104944A (ko)	2011-06-22	2014-08-29	인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)	항-ａｘｌ 항체 및 그의 용도
AU2012273955A1 (en)	2011-06-22	2014-01-09	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Anti-Axl antibodies and uses thereof
EP2543679A1 (en)	2011-07-08	2013-01-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies for the treatment and prevention of thrombosis
EP2543677A1 (en)	2011-07-08	2013-01-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies for the treatment and prevention of thrombosis
EP2543678A1 (en)	2011-07-08	2013-01-09	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies for the treatment and prevention of thrombosis
EP2734236A4 (en)	2011-07-13	2015-04-15	Abbvie Inc	METHOD AND COMPOSITIONS FOR TREATING ASTHMA WITH ANTI-IL-13 ANTIBODIES
JP6120848B2 (ja)	2011-08-15	2017-04-26	メディミューン，エルエルシー	抗ｂ７−ｈ４抗体およびその使用
WO2013033626A2 (en)	2011-08-31	2013-03-07	Trustees Of Dartmouth College	Nkp30 receptor targeted therapeutics
KR20140067052A (ko)	2011-09-09	2014-06-03	암젠 인코퍼레이티드	식도암 및 위암 환자들에서 항-간세포 성장 인자（“ｈｇｆ”） 항체들의 유효성을 예측하기 위한 ｃ―ｍｅｔ 단백질의 용도
US20130108641A1 (en)	2011-09-14	2013-05-02	Sanofi	Anti-gitr antibodies
WO2013038156A1 (en)	2011-09-16	2013-03-21	Ucb Pharma S.A.	Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
AU2012310880B2 (en)	2011-09-21	2015-12-03	Fujirebio Inc.	Antibody against affinity complex
CA2849705A1 (en)	2011-09-23	2013-03-28	Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa	Modified albumin-binding domains and uses thereof to improve pharmacokinetics
CN103906767A (zh)	2011-10-10	2014-07-02	米迪缪尼有限公司	对类风湿关节炎的治疗
EP2771360A1 (en)	2011-10-24	2014-09-03	AbbVie Inc.	Immunobinders directed against sclerostin
WO2013063419A2 (en)	2011-10-28	2013-05-02	The Trustees Of The University Of Pennsylvania	A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
EP2773373B1 (en)	2011-11-01	2018-08-22	Bionomics, Inc.	Methods of blocking cancer stem cell growth
US9221907B2 (en)	2011-11-01	2015-12-29	Bionomics Inc.	Anti-GPR49 monoclonal antibodies
AU2012332587B2 (en)	2011-11-01	2017-02-23	Bionomics, Inc.	Antibodies and methods of treating cancer
US9220774B2 (en)	2011-11-01	2015-12-29	Bionomics Inc.	Methods of treating cancer by administering anti-GPR49 antibodies
ES2861435T3 (es)	2011-11-03	2021-10-06	Univ Pennsylvania	Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas
WO2013070468A1 (en)	2011-11-08	2013-05-16	The Trustees Of The University Of Pennsylvania	Glypican-3-specific antibody and uses thereof
EP2776022A1 (en)	2011-11-08	2014-09-17	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	New treatment for neurodegenerative diseases
EP2776565A1 (en)	2011-11-08	2014-09-17	Quark Pharmaceuticals, Inc.	Methods and compositions for treating diseases, disorders or injury of the nervous system
EP2776838A1 (en)	2011-11-08	2014-09-17	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Early diagnostic of neurodegenerative diseases
UA112203C2 (uk)	2011-11-11	2016-08-10	Юсб Фарма С.А.	Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
DK2776466T3 (da)	2011-11-11	2017-11-20	Ucb Biopharma Sprl	Albuminbindende antistoffer og bindingsfragmenter deraf
EP2599496A1 (en)	2011-11-30	2013-06-05	Kenta Biotech AG	Novel targets of Acinetobacter baumannii
AU2012347972B2 (en)	2011-12-05	2018-05-10	X-Body, Inc.	PDGF receptor beta binding polypeptides
RU2632108C2 (ru)	2011-12-08	2017-10-02	Биотест Аг	Применения иммуноконъюгатов, мишенью которых является cd138
US11147852B2 (en)	2011-12-23	2021-10-19	Pfizer Inc.	Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
AU2012356894B2 (en)	2011-12-23	2018-01-18	Araris Biotech Ltd.	Enzymatic conjugation of polypeptides
US20150030602A1 (en)	2011-12-23	2015-01-29	Phenoquest Ag	Antibodies for the treatment and diagnosis of affective and anxiety disorders
CA2861610A1 (en)	2011-12-30	2013-07-04	Abbvie Inc.	Dual specific binding proteins directed against il-13 and/or il-17
US20140363448A1 (en)	2012-01-02	2014-12-11	Novartis Ag	Cdcp1 and breast cancer
US10800847B2 (en)	2012-01-11	2020-10-13	Dr. Mepur Ravindranath	Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US20130177574A1 (en)	2012-01-11	2013-07-11	Paul I. Terasaki Foundation Laboratory	ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
ES2698606T3 (es)	2012-01-20	2019-02-05	Genzyme Corp	Anticuerpos anti-CXCR3
GB201201332D0 (en)	2012-01-26	2012-03-14	Imp Innovations Ltd	Method
IL297229A (en)	2012-01-27	2022-12-01	Abbvie Inc	The composition and method for the diagnosis and treatment of diseases related to the degeneration of nerve cells
JP6602012B2 (ja)	2012-02-10	2019-11-06	シアトルジェネティクスインコーポレーテッド	Ｃｄ３０＋癌の検出と治療
US9550830B2 (en)	2012-02-15	2017-01-24	Novo Nordisk A/S	Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
PL2814844T3 (pl)	2012-02-15	2017-12-29	Novo Nordisk A/S	Przeciwciała wiążące i blokujące receptor aktywujący wykazujący ekspresję na komórkach szpikowych -1 (trem-1)
EP2814842B1 (en)	2012-02-15	2018-08-22	Novo Nordisk A/S	Antibodies that bind peptidoglycan recognition protein 1
GB201203071D0 (en)	2012-02-22	2012-04-04	Ucb Pharma Sa	Biological products
GB201203051D0 (en)	2012-02-22	2012-04-04	Ucb Pharma Sa	Biological products
FR2987627B1 (fr)	2012-03-05	2016-03-18	Splicos	Utilisation de rbm39 comme biomarqueur
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
LT2831113T (lt)	2012-03-28	2018-06-25	Sanofi	Antikūnai prieš bradikinino b1 receptoriaus ligandus
WO2013144240A1 (en)	2012-03-29	2013-10-03	Friedrich Miescher Institute For Biomedical Research	Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
WO2013151649A1 (en)	2012-04-04	2013-10-10	Sialix Inc	Glycan-interacting compounds
US9505833B2 (en)	2012-04-20	2016-11-29	Abbvie Inc.	Human antibodies that bind human TNF-alpha and methods of preparing the same
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
US9334319B2 (en)	2012-04-20	2016-05-10	Abbvie Inc.	Low acidic species compositions
WO2013158273A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Methods to modulate c-terminal lysine variant distribution
WO2013166043A1 (en)	2012-05-02	2013-11-07	Children's Hospital Medical Center	Rejuvenation of precursor cells
WO2013166290A1 (en)	2012-05-04	2013-11-07	Abbvie Biotherapeutics Inc.	P21 biomarker assay
US9790278B2 (en)	2012-05-07	2017-10-17	The Trustees Of Dartmouth College	Anti-B7-H6 antibody, fusion proteins, and methods of using the same
GB201208370D0 (en)	2012-05-14	2012-06-27	Ucb Pharma Sa	Antibodies
AU2013262934B2 (en)	2012-05-14	2018-02-01	Biogen Ma Inc.	LINGO-2 antagonists for treatment of conditions involving motor neurons
ES2766836T3 (es)	2012-05-15	2020-06-15	Eisai Inc	Métodos para el tratamiento de cáncer gástrico
WO2013175276A1 (en)	2012-05-23	2013-11-28	Argen-X B.V	Il-6 binding molecules
WO2013177386A1 (en)	2012-05-24	2013-11-28	Abbvie Biotherapeutics Inc.	Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
US9249182B2 (en)	2012-05-24	2016-02-02	Abbvie, Inc.	Purification of antibodies using hydrophobic interaction chromatography
JP6629069B2 (ja)	2012-06-06	2020-01-15	ゾエティス・エルエルシー	イヌ化抗ｎｇｆ抗体およびその方法
EP2858665A1 (en)	2012-06-06	2015-04-15	Bionor Immuno AS	Vaccine
EP2864355B1 (en)	2012-06-25	2016-10-12	Orega Biotech	Il-17 antagonist antibodies
WO2014001557A1 (en)	2012-06-28	2014-01-03	Ucb Pharma S.A.	A method for identifying compounds of therapeutic interest
WO2014001482A1 (en)	2012-06-29	2014-01-03	Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research	Treating diseases by modulating a specific isoform of mkl1
WO2014006114A1 (en)	2012-07-05	2014-01-09	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	New treatment for neurodegenerative diseases
US10656156B2 (en)	2012-07-05	2020-05-19	Mepur Ravindranath	Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
WO2014006115A1 (en)	2012-07-06	2014-01-09	Novartis Ag	Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
UY34905A (es)	2012-07-12	2014-01-31	Abbvie Inc	Proteínas de unión a il-1
MX2015000426A (es)	2012-07-13	2015-07-14	Univ Pennsylvania	Incremento de actividad de celulas t car mediante cointroduccion de un anticuerpo biespecifico.
US10132799B2 (en)	2012-07-13	2018-11-20	Innate Pharma	Screening of conjugated antibodies
DK3381943T3 (da)	2012-07-25	2022-05-16	Celldex Therapeutics Inc	Anti-kit-antistoffer og anvendelser deraf
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
WO2014035475A1 (en)	2012-09-02	2014-03-06	Abbvie Inc.	Methods to control protein heterogeneity
EP2892928B1 (en)	2012-09-03	2018-05-30	INSERM - Institut National de la Santé et de la Recherche Médicale	Antibodies directed against icos for treating graft-versus-host disease
EP2904106A4 (en)	2012-10-01	2016-05-11	Univ Pennsylvania	COMPOSITIONS AND METHOD FOR TARGETING CURRIC ACIDS FOR THE TREATMENT OF CANCER
NO2760138T3 (fi)	2012-10-01	2018-08-04
US9598489B2 (en)	2012-10-05	2017-03-21	The Trustees Of The Univeristy Of Pennsylvania	Human alpha-folate receptor chimeric antigen receptor
KR102308915B1 (ko)	2012-10-15	2021-10-06	메디뮨 리미티드	아밀로이드 베타에 대한 항체
US9926363B2 (en)	2012-10-24	2018-03-27	National Research Council Of Canada	Anti-campylobacter jejuni antibodies and uses therefor
CA2890263C (en)	2012-11-01	2020-03-10	Abbvie Inc.	Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
WO2014072482A1 (en)	2012-11-09	2014-05-15	Innate Pharma	Recognition tags for tgase-mediated conjugation
CN104884056A (zh)	2012-11-12	2015-09-02	雷德伍德生物科技股份有限公司	用于制备缀合物的化合物和方法
EP2733153A1 (en)	2012-11-15	2014-05-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for the preparation of immunoconjugates and uses thereof
AU2013344464A1 (en)	2012-11-16	2015-05-21	The Regents Of The University Of California	Pictet-Spengler ligation for protein chemical modification
US9310374B2 (en)	2012-11-16	2016-04-12	Redwood Bioscience, Inc.	Hydrazinyl-indole compounds and methods for producing a conjugate
RS60043B1 (sr)	2012-11-20	2020-04-30	Sanofi Sa	Anti-ceacam5 antitela i njihova primena
EP2925779A1 (en)	2012-11-30	2015-10-07	Institut Pasteur	Use of anti-fcyri and/or anti-fcyriia antibodies for treating arthritis, inflammation, thrombocytopenia and allergic shock
US20140154255A1 (en)	2012-11-30	2014-06-05	Abbvie Biotherapeutics Inc.	Anti-vegf antibodies and their uses
US10342869B2 (en)	2012-12-07	2019-07-09	The Regents Of The University Of California	Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk)	2012-12-07	2018-12-26	Санофі	Композиція, яка містить антитіло до cd38 і леналідомід
SG11201504764SA (en)	2012-12-19	2015-07-30	Amplimmune Inc	Anti-human b7-h4 antibodies and their uses
RU2650756C2 (ru)	2012-12-21	2018-04-17	МЕДИММЬЮН, ЭлЭлСи	Антитела к h7cr
WO2014100542A1 (en)	2012-12-21	2014-06-26	Abbvie, Inc.	High-throughput antibody humanization
GB201223276D0 (en)	2012-12-21	2013-02-06	Ucb Pharma Sa	Antibodies and methods of producing same
WO2014102299A2 (en)	2012-12-27	2014-07-03	Sanofi	Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
AU2013375015A1 (en)	2013-01-28	2015-08-13	Evec Inc.	Humanized anti-HMGB1 antibody or antigen-binding fragment thereof
EP2951199A4 (en)	2013-01-31	2016-07-20	Univ Jefferson	Fusion proteins for the modulation of regulatory and effector T cells
US9573988B2 (en)	2013-02-20	2017-02-21	Novartis Ag	Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
CN111139256A (zh)	2013-02-20	2020-05-12	诺华股份有限公司	使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
SG11201506956TA (en)	2013-03-13	2015-10-29	Sanofi Sa	Compositions comprising anti-cd38 antibodies and carfilzomib
US8921526B2 (en)	2013-03-14	2014-12-30	Abbvie, Inc.	Mutated anti-TNFα antibodies and methods of their use
US9499614B2 (en)	2013-03-14	2016-11-22	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
EP2970947A4 (en)	2013-03-14	2016-10-12	Abbott Lab	RECOMBINANT HCV NS3 ANTIGENS AND THEIR MUTANTS FOR ENHANCED ANTIBODY DETECTION
CA2906417C (en)	2013-03-14	2022-06-21	Robert Ziemann	Hcv core lipid binding domain monoclonal antibodies
CA2906421C (en)	2013-03-14	2022-08-16	George J. Dawson	Hcv antigen-antibody combination assay and methods and compositions for use therein
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014145000A2 (en)	2013-03-15	2014-09-18	Abbvie Biotherapeutics Inc.	Anti-cd25 antibodies and their uses
EP3623380A1 (en)	2013-03-15	2020-03-18	Michael C. Milone	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
EP2968582B1 (en)	2013-03-15	2020-07-01	Innate Pharma	Solid phase tgase-mediated conjugation of antibodies
US9446105B2 (en)	2013-03-15	2016-09-20	The Trustees Of The University Of Pennsylvania	Chimeric antigen receptor specific for folate receptor β
US20150010538A1 (en)	2013-03-15	2015-01-08	Abbvie Biotherapeutics Inc.	Anti-cd25 antibodies and their uses
WO2014144763A2 (en)	2013-03-15	2014-09-18	Memorial Sloan Kettering Cancer Center	High affinity anti-gd2 antibodies
CN105324396A (zh)	2013-03-15	2016-02-10	艾伯维公司	针对IL-1β和/或IL-17的双重特异性结合蛋白
WO2014144960A2 (en)	2013-03-15	2014-09-18	Abbvie Biotherapeutics Inc.	Fc variants
UY35468A (es)	2013-03-16	2014-10-31	Novartis Ag	Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
TWI679019B (zh)	2013-04-29	2019-12-11	法商賽諾菲公司	抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
SG10201913751RA (en)	2013-05-06	2020-03-30	Scholar Rock Inc	Compositions and methods for growth factor modulation
US10005839B2 (en)	2013-05-17	2018-06-26	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Antagonist of the BTLA/HVEM interaction for use in therapy
CN106414489A (zh)	2013-05-24	2017-02-15	米迪缪尼有限公司	抗-b7-h5抗体及其用途
EP3003390B1 (en)	2013-06-06	2021-07-07	Pierre Fabre Médicament	Anti-c10orf54 antibodies and uses thereof
US9499628B2 (en)	2013-06-14	2016-11-22	Children's Hospital Medical Center	Method of boosting the immune response in neonates
US10071169B2 (en)	2013-06-20	2018-09-11	Innate Pharma	Enzymatic conjugation of polypeptides
AU2014283185B2 (en)	2013-06-21	2019-05-02	Araris Biotech Ltd.	Enzymatic conjugation of polypeptides
WO2015007337A1 (en)	2013-07-19	2015-01-22	Bionor Immuno As	Method for the vaccination against hiv
CA2918795A1 (en)	2013-07-25	2015-01-29	Cytomx Therapeutics, Inc.	Multispecific antibodies, multispecific activatable antibodies and methods of using the same
US20160178610A1 (en)	2013-08-07	2016-06-23	Friedrich Miescher Institute For Biomedical Research	New screening method for the treatment Friedreich's ataxia
TWI592426B (zh)	2013-08-13	2017-07-21	賽諾菲公司	胞漿素原活化素抑制劑－１（ｐａｉ－１）之抗體及其用途
BR112016002753A2 (pt)	2013-08-13	2017-11-21	Sanofi Sa	anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
GB201315487D0 (en)	2013-08-30	2013-10-16	Ucb Pharma Sa	Antibodies
EP3042667A4 (en)	2013-09-04	2017-04-05	Osaka University	Dpp-4-targeting vaccine for treating diabetes
WO2015035044A2 (en)	2013-09-04	2015-03-12	Abbvie Biotherapeutics Inc.	Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
US9481729B2 (en)	2013-09-11	2016-11-01	The University Of Hong Kong	Anti-HER2 and anti-IGF-IR BI-specific antibodies and uses thereof
JP6599338B2 (ja)	2013-09-16	2019-10-30	ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）	Ｈｂｖ感染および関連症状の治療のための免疫エフェクター細胞表面抗原およびｈｂｖ抗原結合性の二重特異性または多重特異性ポリペプチド
US9598667B2 (en)	2013-10-04	2017-03-21	Abbvie Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
EP3372236A1 (en)	2013-10-25	2018-09-12	PsiOxus Therapeutics Limited	Oncolytic adenoviruses armed with heterologous genes
EP3063317B1 (en)	2013-10-28	2020-06-03	DOTS Technology Corp.	Allergen detection
US9580504B1 (en)	2013-11-07	2017-02-28	Curetech Ltd.	Pidilizumab monoclonal antibody therapy following stem cell transplantation
JP6449876B2 (ja)	2013-11-07	2019-01-09	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	ニューレグリンに対して非競合的でアロステリックな抗ヒトｈｅｒ３抗体及びその使用
GB201320066D0 (en)	2013-11-13	2013-12-25	Ucb Pharma Sa	Biological products
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
US9493413B2 (en)	2013-11-27	2016-11-15	Redwood Bioscience, Inc.	Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
EP3080160B1 (en)	2013-12-13	2022-07-06	Rijksuniversiteit Groningen	Antibodies against staphylococcus aureus and uses thereof
WO2015095143A1 (en)	2013-12-16	2015-06-25	The University Of North Carolina At Chapel Hill	Depletion of plasmacytoid dendritic cells
US9914769B2 (en)	2014-07-15	2018-03-13	Kymab Limited	Precision medicine for cholesterol treatment
US8992927B1 (en)	2014-07-15	2015-03-31	Kymab Limited	Targeting human NAV1.7 variants for treatment of pain
US9045545B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986694B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Targeting human nav1.7 variants for treatment of pain
US9067998B1 (en)	2014-07-15	2015-06-30	Kymab Limited	Targeting PD-1 variants for treatment of cancer
WO2015090229A1 (en)	2013-12-20	2015-06-25	Novartis Ag	Regulatable chimeric antigen receptor
ES2778498T3 (es)	2013-12-20	2020-08-10	Hoffmann La Roche	Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
KR101836756B1 (ko)	2013-12-27	2018-03-08	오사카 유니버시티	Il-17a를 표적화하는 백신
EP2893939A1 (en)	2014-01-10	2015-07-15	Netris Pharma	Anti-netrin-1 antibody
WO2015112626A1 (en)	2014-01-21	2015-07-30	June Carl H	Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
EP3110445A4 (en)	2014-02-25	2017-09-27	Immunomedics, Inc.	Humanized rfb4 anti-cd22 antibody
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
AU2014385799B2 (en)	2014-03-06	2020-10-22	National Research Council Of Canada	Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
US10100117B2 (en)	2014-03-06	2018-10-16	National Research Council Of Canada	Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
PE20161311A1 (es)	2014-03-06	2016-11-25	Nat Res Council Canada	Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
US9738702B2 (en)	2014-03-14	2017-08-22	Janssen Biotech, Inc.	Antibodies with improved half-life in ferrets
US20170335281A1 (en)	2014-03-15	2017-11-23	Novartis Ag	Treatment of cancer using chimeric antigen receptor
US20170081411A1 (en)	2014-03-15	2017-03-23	Novartis Ag	Regulatable chimeric antigen receptor
CA2943242A1 (en)	2014-03-21	2015-09-24	X-Body, Inc.	Bi-specific antigen-binding polypeptides
WO2015153916A1 (en)	2014-04-04	2015-10-08	Bionomics, Inc.	Humanized antibodies that bind lgr5
PL3888674T3 (pl)	2014-04-07	2024-09-23	Novartis Ag	Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
GB201406608D0 (en)	2014-04-12	2014-05-28	Psioxus Therapeutics Ltd	Virus
US10544231B2 (en)	2014-04-16	2020-01-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies for the prevention or the treatment of bleeding episodes
CA2983794A1 (en)	2014-04-25	2015-10-29	The Brigham And Women's Hospital, Inc.	Methods to manipulate alpha-fetoprotein (afp)
MX375284B (es)	2014-04-30	2025-03-06	Pfizer Inc	Conjugados de anticuerpo-fármaco anti-proteína tirosina quinasa 7 (anti-ptk7).
ES2869459T3 (es)	2014-05-16	2021-10-25	Medimmune Llc	Moléculas con unión a receptor de fc de neonato alterada que tiene propiedades terapéuticas y de diagnóstico potenciadas
EP3498295A1 (en)	2014-05-28	2019-06-19	Agenus Inc.	Anti-gitr antibodies and methods of use thereof
GB201409558D0 (en)	2014-05-29	2014-07-16	Ucb Biopharma Sprl	Method
CA2947484C (en)	2014-06-06	2023-05-09	Redwood Bioscience, Inc.	Anti-her2 antibody-maytansine conjugates and methods of use thereof
EP3154579A1 (en)	2014-06-13	2017-04-19	Friedrich Miescher Institute for Biomedical Research	New treatment against influenza virus
NL2013661B1 (en)	2014-10-21	2016-10-05	Ablynx Nv	KV1.3 Binding immunoglobulins.
US10308935B2 (en)	2014-06-23	2019-06-04	Friedrich Miescher Institute For Biomedical Research	Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
GB201411320D0 (en)	2014-06-25	2014-08-06	Ucb Biopharma Sprl	Antibody construct
AR100978A1 (es)	2014-06-26	2016-11-16	Hoffmann La Roche	LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
US20170165261A1 (en)	2014-07-01	2017-06-15	Brian Arthur Hemmings	Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
US9139648B1 (en)	2014-07-15	2015-09-22	Kymab Limited	Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412658D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
GB201412659D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
WO2016009086A1 (en)	2014-07-17	2016-01-21	Novo Nordisk A/S	Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
EP3172234B1 (en)	2014-07-21	2020-04-08	Novartis AG	Treatment of cancer using a cd33 chimeric antigen receptor
WO2016014553A1 (en)	2014-07-21	2016-01-28	Novartis Ag	Sortase synthesized chimeric antigen receptors
WO2016014565A2 (en)	2014-07-21	2016-01-28	Novartis Ag	Treatment of cancer using humanized anti-bcma chimeric antigen receptor
EP3193915A1 (en)	2014-07-21	2017-07-26	Novartis AG	Combinations of low, immune enhancing. doses of mtor inhibitors and cars
WO2016014974A2 (en)	2014-07-25	2016-01-28	Cytomx Therapeutics, Inc.	Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
MX367787B (es)	2014-07-29	2019-09-06	Cellectis	Receptores de antígenos quimericos ror1 (ntrkr1) específicos para inmunoterapia del cáncer.
JP2017522893A (ja)	2014-07-31	2017-08-17	セレクティスＣｅｌｌｅｃｔｉｓ	Ｒｏｒ１特異的多重鎖キメラ抗原受容体
EP3660042B1 (en)	2014-07-31	2023-01-11	Novartis AG	Subset-optimized chimeric antigen receptor-containing t-cells
MA44560B2 (fr)	2014-07-31	2021-01-29	Sanofi Sa	Anticorps anti-cd38 spécifiques pour le traitement de cancers humains
JP6919118B2 (ja)	2014-08-14	2021-08-18	ノバルティスアーゲー	ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
RU2020117196A (ru)	2014-08-19	2020-10-15	Новартис Аг	Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
SG11201701328XA (en)	2014-09-02	2017-03-30	Immunogen Inc	Methods for formulating antibody drug conjugate compositions
ES2777305T3 (es)	2014-09-04	2020-08-04	Cellectis	Receptores de antígeno quiméricos específicos de la glicoproteína trofoblástica (5T4, TPBG) para inmunoterapia contra el cáncer
PT3189081T (pt)	2014-09-05	2020-05-25	Janssen Pharmaceutica Nv	Agentes de ligação a cd123 e seus usos
WO2016043577A1 (en)	2014-09-16	2016-03-24	Academisch Medisch Centrum	Ig-like molecules binding to bmp4
US10577417B2 (en)	2014-09-17	2020-03-03	Novartis Ag	Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US10080790B2 (en)	2014-09-19	2018-09-25	The Regents Of The University Of Michigan	Staphylococcus aureus materials and methods
US20170298360A1 (en)	2014-09-24	2017-10-19	Friedrich Miescher Institute For Biomedical Research	Lats and breast cancer
US10365280B2 (en)	2014-10-02	2019-07-30	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating malignancies
WO2016055941A1 (en)	2014-10-10	2016-04-14	National Research Council Of Canada	Anti-tau antibody and uses thereof
US10316094B2 (en)	2014-10-24	2019-06-11	The Board Of Trustees Of The Leland Stanford Junior University	Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance
AU2015339743C1 (en)	2014-10-31	2021-04-22	The Trustees Of The University Of Pennsylvania	Altering gene expression in modified T cells and uses thereof
AU2015339106B2 (en)	2014-10-31	2020-07-02	The Trustees Of The University Of Pennsylvania	Compositions and methods of stimulating and expanding T cells
WO2016070089A2 (en)	2014-10-31	2016-05-06	Abbvie Biotherapeutics Inc.	Anti-cs1 antibodies and antibody drug conjugates
US11072644B2 (en)	2014-11-12	2021-07-27	Allogene Therapeutics, Inc.	Inhibitory chimeric antigen receptors
EP4183806A3 (en)	2014-11-12	2023-08-02	Seagen Inc.	Glycan-interacting compounds and methods of use
US9879087B2 (en)	2014-11-12	2018-01-30	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
US20170269092A1 (en)	2014-12-02	2017-09-21	Cemm - Forschungszentrum Fuer Molekulare Medizin Gmbh	Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
WO2016090034A2 (en)	2014-12-03	2016-06-09	Novartis Ag	Methods for b cell preconditioning in car therapy
EP3546567A1 (en)	2014-12-06	2019-10-02	GEMoaB Monoclonals GmbH	Genetic modified pluri- or multipotent stem cells and uses thereof
KR20170093943A (ko)	2014-12-09	2017-08-16	애브비 인코포레이티드	낮은 세포 투과성을 갖는 bcl xl 억제 화합물 및 이를 포함하는 항체 약물 접합체
EP3735990A1 (en)	2014-12-09	2020-11-11	Abbvie Inc.	Antibody drug conjugates with cell permeable bcl-xl inhibitors
US11001625B2 (en)	2014-12-10	2021-05-11	Tufts University	VHH based binding antibodies for anthrax and botulinum toxins and methods of making and using therefor
KR20170093182A (ko)	2014-12-11	2017-08-14	인바이오모션 에스.엘.	인간 c-maf에 대한 결합 구성원
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
KR102693806B1 (ko)	2014-12-11	2024-08-09	피에르 파브르 메디카먼트	항-c10orf54 항체들 및 그들의 용도들
CN107406509B (zh)	2014-12-19	2021-10-29	凯奥目生物科学株式会社	包含结合至5t4和cd3的三个结合结构域的融合蛋白
EP3233897B1 (en)	2014-12-19	2021-02-17	Universite de Nantes	Anti il-34 antibodies
US10221248B2 (en)	2014-12-22	2019-03-05	The Rockefeller University	Anti-MERTK agonistic antibodies and uses thereof
US10435467B2 (en)	2015-01-08	2019-10-08	Biogen Ma Inc.	LINGO-1 antagonists and uses for treatment of demyelinating disorders
JP7152156B2 (ja)	2015-01-14	2022-10-12	ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド	抗ｌａｐモノクローナル抗体による癌の処置
WO2016116626A1 (en)	2015-01-23	2016-07-28	Sanofi	Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
BR112017013981A2 (pt)	2015-01-26	2018-01-02	Cellectis	receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
US10828353B2 (en)	2015-01-31	2020-11-10	The Trustees Of The University Of Pennsylvania	Compositions and methods for T cell delivery of therapeutic molecules
WO2016126608A1 (en)	2015-02-02	2016-08-11	Novartis Ag	Car-expressing cells against multiple tumor antigens and uses thereof
US10266584B2 (en)	2015-02-09	2019-04-23	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Antibodies specific to glycoprotein (GP) of Ebolavirus and uses for the treatment and diagnosis of ebola virus infection
DE112016001013T5 (de)	2015-03-03	2017-12-21	Kymab Limited	Antikörper, verwendungen und verfahren
US11155601B2 (en)	2015-03-06	2021-10-26	CSL Behring Lengnau AG	Modified von Willebrand factor having improved half-life
EP3268125A4 (en)	2015-03-13	2018-08-15	President and Fellows of Harvard College	Determination of cells using amplification
CN107667120B (zh)	2015-03-17	2022-03-08	纪念斯隆-凯特林癌症中心	抗muc16抗体及其应用
US10744157B2 (en)	2015-03-26	2020-08-18	The Trustees Of Dartmouth College	Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
WO2016162368A1 (en)	2015-04-07	2016-10-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Non-invasive imaging of tumor pd-l1 expression
PL3280729T3 (pl)	2015-04-08	2022-08-22	Novartis Ag	Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
GB201506870D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
GB201506869D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
US12128069B2 (en)	2015-04-23	2024-10-29	The Trustees Of The University Of Pennsylvania	Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CA2983898A1 (en)	2015-04-28	2016-11-03	Mitsubishi Tanabe Pharma Corporation	Rgma binding protein and use thereof
CA2982427A1 (en)	2015-04-30	2016-11-03	President And Fellows Of Harvard College	Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
US20180140694A1 (en)	2015-05-04	2018-05-24	Bionor Immuno As	Dosage regimen for hiv vaccine
MA42059A (fr)	2015-05-06	2018-03-14	Janssen Biotech Inc	Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci
CN115109158A (zh)	2015-05-07	2022-09-27	阿吉纳斯公司	抗ox40抗体及其使用方法
GB201508180D0 (en)	2015-05-13	2015-06-24	Ucb Biopharma Sprl	Antibodies
CN115043943A (zh)	2015-05-15	2022-09-13	综合医院公司	拮抗性抗肿瘤坏死因子受体超家族抗体
BR112017024757A2 (pt)	2015-05-18	2018-11-13	TCR2 Therapeutics Inc.	composições e métodos para reprogramação de tcr utilizando proteínas de fusão
AU2016263513A1 (en)	2015-05-20	2017-11-23	Cellectis	Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy
JP6688551B2 (ja)	2015-05-21	2020-04-28	ハープーンセラピューティクス，インク．	三重特異性結合タンパク質と使用方法
CN107660152B (zh)	2015-05-27	2021-11-05	Ucb生物制药私人有限公司	用于治疗神经系统疾病的方法
CN113603782A (zh)	2015-05-29	2021-11-05	艾伯维公司	抗cd40抗体及其用途
WO2016196237A1 (en)	2015-05-29	2016-12-08	Agenus Inc.	Anti-ctla-4 antibodies and methods of use thereof
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
GB201510758D0 (en)	2015-06-18	2015-08-05	Ucb Biopharma Sprl	Novel TNFa structure for use in therapy
ES2809728T3 (es)	2015-06-24	2021-03-05	Hoffmann La Roche	Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
MA41670A1 (fr)	2015-07-06	2018-05-31	Ucb Biopharma Sprl	Anticorps se liant a tau
JP6937289B2 (ja)	2015-07-06	2021-09-22	ユーシービーバイオファルマエスアールエル	Ｔａｕ結合抗体
US20180201687A1 (en)	2015-07-07	2018-07-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies having specificity to myosin 18a and uses thereof
GB201601073D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies
GB201601075D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies molecules
GB201601077D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibody molecule
WO2017027392A1 (en)	2015-08-07	2017-02-16	Novartis Ag	Treatment of cancer using chimeric cd3 receptor proteins
US10509035B2 (en)	2015-08-07	2019-12-17	Gamamabs Pharma Sa	Antibodies, antibody drug conjugates and methods of use
BR112018002600A2 (pt)	2015-08-11	2018-10-23	Cellectis	células para imunoterapia modificadas para direcionamento ao antígeno cd38 e para inativação do gene cd38
US11649435B2 (en)	2015-08-28	2023-05-16	The Trustees Of The University Of Pennsylvania	Methods and compositions for cells expressing a chimeric intracellular signaling molecule
WO2017040324A1 (en)	2015-08-28	2017-03-09	The Trustees Of The University Of Pennsylvania	Methods and compositions for cells expressing a chimeric intracellular signaling molecule
PE20181322A1 (es)	2015-09-01	2018-08-14	Agenus Inc	Anticuerpo anti-pd1 y sus metodos de uso
JP7002446B2 (ja)	2015-09-21	2022-03-04	アプティーボリサーチアンドデベロップメントエルエルシー	Ｃｄ３結合ポリペプチド
WO2017060397A1 (en)	2015-10-09	2017-04-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the survival time of subjects suffering from melanoma metastases
US10149887B2 (en)	2015-10-23	2018-12-11	Canbas Co., Ltd.	Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
US11492396B2 (en)	2015-10-27	2022-11-08	UCB Biopharma SRL	Methods of treatment using anti-IL-17A/F antibodies
EP3368566A1 (en)	2015-10-28	2018-09-05	Friedrich Miescher Institute for Biomedical Research	Tenascin-w and biliary tract cancers
EP3368567A4 (en)	2015-10-28	2019-05-22	Yale University	HUMANIZED ANTI-DKK2 ANTIBODIES AND USES THEREOF
AR106543A1 (es)	2015-11-02	2018-01-24	Netris Pharma	Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético
US11235063B2 (en)	2015-11-03	2022-02-01	Merck Patent Gmbh	Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
WO2017079419A1 (en)	2015-11-05	2017-05-11	The Regents Of The University Of California	Cells labelled with lipid conjugates and methods of use thereof
MX2018005785A (es)	2015-11-09	2019-04-04	Scherer Technologies Llc R P	Conjugados de anticuerpo anti-cd22-maytansina y metodos de uso de los mismos.
US11028181B2 (en)	2015-11-12	2021-06-08	Seagen Inc.	Glycan-interacting compounds and methods of use
PT3380525T (pt)	2015-11-25	2024-02-05	Immunogen Inc	Formulações farmacêuticas e métodos que as utilizam
ES2810755T3 (es)	2015-11-30	2021-03-09	Abbvie Inc	Conjugados fármaco-anticuerpo anti-lrrc15 humano y métodos para su uso
EP3383910A1 (en)	2015-11-30	2018-10-10	AbbVie Inc.	ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
JP7090545B2 (ja)	2015-12-02	2022-06-24	ストキューブアンドシーオー．，インコーポレイテッド	Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにそれらの治療的使用
CN108925136B (zh)	2015-12-02	2022-02-01	斯特赛恩斯公司	特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体
GB201521383D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl And Ucb Celltech	Method
GB201521389D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Method
GB201521393D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201521391D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201521382D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
US20180271998A1 (en)	2015-12-04	2018-09-27	Merrimack Pharmaceuticals, Inc.	Disulfide-stabilized fabs
US11052111B2 (en)	2015-12-08	2021-07-06	Chimera Bioengineering, Inc.	Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
EP3389699B1 (en)	2015-12-15	2024-05-01	OncoC4, Inc.	Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
GB201522394D0 (en)	2015-12-18	2016-02-03	Ucb Biopharma Sprl	Antibodies
EP3184544A1 (en)	2015-12-23	2017-06-28	Julius-Maximilians-Universität Würzburg	Glycoprotein v inhibitors for use as coagulants
MA43550A (fr)	2015-12-31	2018-11-07	Syncerus S A R L	Compositions et procédés d'évaluation du risque d'apparition d'un cancer
EP3405492B1 (en)	2016-01-21	2020-10-21	Novartis AG	Multispecific molecules targeting cll-1
US10465003B2 (en)	2016-02-05	2019-11-05	Janssen Biotech, Inc.	Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
GB201602413D0 (en)	2016-02-10	2016-03-23	Nascient Ltd	Method
JP2019513008A (ja)	2016-02-26	2019-05-23	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	Ｂｔｌａに対して特異性を有する抗体及びその使用
BR112018067292A2 (pt)	2016-03-02	2019-01-02	Idexx Lab Inc	métodos e composições para a detecção e o diagnóstico de doença renal e doença periodontal
SG11201807489PA (en)	2016-03-04	2018-09-27	Novartis Ag	Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
CA3017418A1 (en)	2016-03-15	2017-09-21	Astrazeneca Ab	Combination of a bace inhibitor and an antibody or antigen-binding fragment for the treatment of a disorder associated with the accumulation of amyloid beta
EP3430044A1 (en)	2016-03-17	2019-01-23	Numab Innovation AG	Anti-tnf alpha -antibodies and functional fragments thereof
SI3219726T1 (sl)	2016-03-17	2021-02-26	Tillotts Pharma Ag	Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
PT3219727T (pt)	2016-03-17	2021-01-21	Tillotts Pharma Ag	Anticorpos anti-tnf alfa e fragmentos funcionais dos mesmos
US10787508B2 (en)	2016-03-17	2020-09-29	Numab Innovation Ag	Anti-TNFα-antibodies and functional fragments thereof
EA039201B1 (ru)	2016-03-17	2021-12-16	Нумаб Инновейшн Аг	Антитела к фно и их функциональные фрагменты
JP2019509322A (ja)	2016-03-22	2019-04-04	バイオノミクスリミテッド	抗ｌｇｒ５モノクローナル抗体の投与
US11549099B2 (en)	2016-03-23	2023-01-10	Novartis Ag	Cell secreted minibodies and uses thereof
WO2017172981A2 (en)	2016-03-29	2017-10-05	University Of Southern California	Chimeric antigen receptors targeting cancer
EP3443096B1 (en)	2016-04-15	2023-03-01	Novartis AG	Compositions and methods for selective expression of chimeric antigen receptors
AU2017258097B2 (en)	2016-04-27	2019-10-24	Abbvie Inc.	Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies
WO2017191062A1 (en)	2016-05-01	2017-11-09	Ucb Biopharma Sprl	Affinity engineered serum protein carrier binding domain
WO2017194568A1 (en)	2016-05-11	2017-11-16	Sanofi	Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
RS61659B1 (sr)	2016-05-17	2021-04-29	Abbvie Biotherapeutics Inc	Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
US11623958B2 (en)	2016-05-20	2023-04-11	Harpoon Therapeutics, Inc.	Single chain variable fragment CD3 binding proteins
CN119060177A (zh)	2016-05-20	2024-12-03	哈普恩治疗公司	单结构域血清白蛋白结合蛋白质
WO2017205465A2 (en)	2016-05-24	2017-11-30	Griswold Karl Edwin	Antibodies and methods of making same
WO2017205745A1 (en)	2016-05-27	2017-11-30	Abbvie Biotherapeutics Inc.	Anti-4-1bb antibodies and their uses
SG11201810023QA (en)	2016-05-27	2018-12-28	Agenus Inc	Anti-tim-3 antibodies and methods of use thereof
PT3464361T (pt)	2016-05-27	2021-12-27	Abbvie Biotherapeutics Inc	Anticorpos anti-cd40 e suas utilizações
EP3464375A2 (en)	2016-06-02	2019-04-10	Novartis AG	Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
EP3469000A1 (en)	2016-06-08	2019-04-17	AbbVie Inc.	Anti-b7-h3 antibodies and antibody drug conjugates
SG10201914119TA (en)	2016-06-08	2020-02-27	Abbvie Inc	Anti-b7-h3 antibodies and antibody drug conjugates
WO2017214322A1 (en)	2016-06-08	2017-12-14	Abbvie Inc.	Anti-b7-h3 antibodies and antibody drug conjugates
GB201610198D0 (en)	2016-06-10	2016-07-27	Ucb Biopharma Sprl	Anti-ige antibodies
MY190771A (en)	2016-06-13	2022-05-12	I Mab Biopharma Us Ltd	Anti-pd-l1 antibodies and uses thereof
EP3471754A1 (en)	2016-06-20	2019-04-24	Kymab Limited	Anti-pd-l1 antibodies
BR112018076767A2 (pt)	2016-06-21	2019-04-02	Teneobio, Inc.	anticorpos de ligação a cd3
CA3030099A1 (en)	2016-07-08	2018-01-11	Staten Biotechnology B.V.	Anti-apoc3 antibodies and methods of use thereof
JP2019532017A (ja)	2016-07-14	2019-11-07	フレッドハッチンソンキャンサーリサーチセンター	がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物
WO2018013918A2 (en)	2016-07-15	2018-01-18	Novartis Ag	Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
CA3031289A1 (en)	2016-07-18	2018-01-25	Helix Biopharma Corp.	Car immune cells to treat cancer
TWI790206B (zh)	2016-07-18	2023-01-21	法商賽諾菲公司	特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
WO2018017964A2 (en)	2016-07-21	2018-01-25	Emory University	Ebola virus antibodies and binding agents derived therefrom
US20190151365A1 (en)	2016-07-28	2019-05-23	Novartis Ag	Combination therapies of chimeric antigen receptors and pd-1 inhibitors
BR112019001693A2 (pt)	2016-07-29	2019-07-02	Ct Hospitalier Universitaire Toulouse	anticorpos direcionados a macrófagos associados a tumores e seus usos
EP3490590A2 (en)	2016-08-01	2019-06-05	Novartis AG	Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
WO2018026953A1 (en)	2016-08-02	2018-02-08	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
EP3504244A4 (en)	2016-08-26	2020-08-19	Agency for Science, Technology and Research	MACROPHAGE-STIMULATING PROTEIN RECEPTOR ANTIBODIES (OR OF NANTAIS ORIGINAL RON-RECEPTOR) AND THEIR USES
KR102427563B1 (ko)	2016-08-29	2022-08-03	싸이오서스 테라퓨틱스 엘티디.	이중특이성 T 세포 활성화제(Bispecific T cell activator)가 보강된 아데노바이러스
MX2019002946A (es)	2016-09-14	2019-09-26	Abbvie Biotherapeutics Inc	Anticuerpos anti-pd-1 y sus usos.
DK4050034T3 (da)	2016-09-14	2024-06-03	Teneoone Inc	Cd3-bindende antistoffer
US11098113B2 (en)	2016-09-15	2021-08-24	Vib Vzw	Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
US10647767B2 (en)	2016-09-19	2020-05-12	I-Mab Biopharma Co., Ltd.	Anti-GM-CSF antibodies and uses thereof
JP7069177B2 (ja)	2016-09-21	2022-05-17	ネクストキュアインコーポレイテッド	シグレック－１５に対する抗体及びその使用方法
EP4360714A3 (en)	2016-09-21	2024-07-24	Nextcure, Inc.	Antibodies for siglec-15 and methods of use thereof
GB201616596D0 (en)	2016-09-29	2016-11-16	Nascient Limited	Epitope and antibodies
EP3445787B1 (en)	2016-10-07	2020-12-02	TCR2 Therapeutics Inc.	Compositions and methods for t-cell receptors reprogramming using fusion proteins
AU2017341047B2 (en)	2016-10-07	2024-10-10	Novartis Ag	Chimeric antigen receptors for the treatment of cancer
TWI843168B (zh)	2016-10-11	2024-05-21	美商艾吉納斯公司	抗ｌａｇ－３抗體及其使用方法
US11007254B2 (en)	2016-10-17	2021-05-18	Musc Foundation For Research Development	Compositions and methods for treating central nervous system injury
JP2020500214A (ja)	2016-11-02	2020-01-09	イミュノジェン・インコーポレーテッド	抗体薬物複合体とｐａｒｐ阻害剤との併用治療
WO2018083257A1 (en)	2016-11-03	2018-05-11	Psioxus Therapeutics Limited	Oncolytic adenovirus encoding transgenes
EP3534947A1 (en)	2016-11-03	2019-09-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018083258A1 (en)	2016-11-03	2018-05-11	Psioxus Therapeutics Limited	Oncolytic adenovirus encoding at least three transgenes
KR102539159B1 (ko)	2016-11-07	2023-06-02	주식회사 뉴라클사이언스	서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
WO2018094143A1 (en)	2016-11-17	2018-05-24	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
WO2018091720A1 (en)	2016-11-21	2018-05-24	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the prophylactic treatment of metastases
JP7291396B2 (ja)	2016-11-22	2023-06-15	ティーシーアール２セラピューティクスインク．	融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
US10899842B2 (en)	2016-11-23	2021-01-26	Immunoah Therapeutics, Inc.	4-1BB binding proteins and uses thereof
BR112019010602A2 (pt)	2016-11-23	2019-12-17	Harpoon Therapeutics Inc	proteínas trispecíficas para psma e métodos de uso
AU2017363300A1 (en)	2016-11-23	2019-06-20	Harpoon Therapeutics, Inc.	Prostate specific membrane antigen binding protein
MA50949B1 (fr)	2016-12-07	2023-12-29	Memorial Sloan Kettering Cancer Center	Anticorps anti-ctla-4 et leurs procédés d'utilisation
PE20190921A1 (es)	2016-12-07	2019-06-26	Agenus Inc	Anticuerpos y metodos de su utilizacion
AR110526A1 (es)	2016-12-15	2019-04-10	Abbvie Biotherapeutics Inc	Anticuerpos anti-ox40 y sus usos en el tratamiento del cáncer
GB201621635D0 (en)	2016-12-19	2017-02-01	Ucb Biopharma Sprl	Crystal structure
KR102745676B1 (ko)	2016-12-21	2024-12-24	테네오바이오, 인코포레이티드	항-bcma 중쇄-단독 항체
KR20190095943A (ko)	2016-12-22	2019-08-16	사노피	고갈 활성을 갖는 인간화 cxcr3 항체 및 이의 사용 방법
TW201840585A (zh)	2016-12-22	2018-11-16	法商賽諾菲公司	用於白斑病的治療的抗人cxcr3抗體
KR102679324B1 (ko)	2017-01-05	2024-06-28	네트리 파르마	네트린-1 간섭 약물과 면역 관문 억제제 약물의 조합 치료
CN110709419B (zh)	2017-01-06	2023-11-28	博奥信生物技术（南京）有限公司	Erbb2抗体及其用途
CN117586401A (zh)	2017-01-20	2024-02-23	大有华夏生物医药集团有限公司	抗pd-1抗体及其用途
DK3383916T3 (da)	2017-01-24	2022-03-28	I Mab Biopharma Us Ltd	Anti-CD73-antistoffer og anvendelser deraf
WO2018140725A1 (en)	2017-01-26	2018-08-02	Novartis Ag	Cd28 compositions and methods for chimeric antigen receptor therapy
CA3052095A1 (en)	2017-01-30	2018-08-02	Janssen Biotech, Inc.	Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis
US20190375815A1 (en)	2017-01-31	2019-12-12	Novartis Ag	Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
EP3354278A1 (en)	2017-01-31	2018-08-01	Sanofi	Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide
KR20240038148A (ko)	2017-02-07	2024-03-22	얀센 바이오테크 인코포레이티드	활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
WO2018151841A1 (en)	2017-02-17	2018-08-23	Sanofi	Multispecific binding molecules having specificity to dystroglycan and laminin-2
KR102654105B1 (ko)	2017-02-17	2024-04-04	사노피	디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
US11535668B2 (en)	2017-02-28	2022-12-27	Harpoon Therapeutics, Inc.	Inducible monovalent antigen binding protein
EP3589654A1 (en)	2017-03-02	2020-01-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies having specificity to nectin-4 and uses thereof
KR102653141B1 (ko)	2017-03-03	2024-04-01	씨젠 인크.	글리칸-상호작용 화합물 및 사용 방법
KR102584011B1 (ko)	2017-03-16	2023-09-27	이나뜨 파르마 에스.에이.	암 치료를 위한 조성물 및 방법
TWI808963B (zh)	2017-03-22	2023-07-21	法商賽諾菲公司	使用人類化抗ｃｘｃｒ５抗體治療狼瘡
BR112019020185A2 (pt)	2017-03-27	2020-06-02	Celgene Corporation	Métodos e composições para redução da imunogenicidade
WO2018183366A1 (en)	2017-03-28	2018-10-04	Syndax Pharmaceuticals, Inc.	Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
CN110546166B (zh)	2017-04-13	2024-03-29	艾吉纳斯公司	抗cd137抗体和其使用方法
BR112019021472A8 (pt)	2017-04-14	2023-05-02	Inst Curie	Compostos de ligação ao amhrii para prevenção ou tratamento de cânceres
KR20250017758A (ko)	2017-04-14	2025-02-04	엑셀리시스, 인코포레이티드	폐암을 예방 또는 치료하기 위한 amhrii-결합 화합물
WO2018193427A1 (en)	2017-04-21	2018-10-25	Staten Biotechnology B.V.	Anti-apoc3 antibodies and methods of use thereof
US20230140818A1 (en)	2017-04-27	2023-05-04	The University Of Hong Kong	Use of hcn inhibitors for treatment of cancer
EP3615055A1 (en)	2017-04-28	2020-03-04	Novartis AG	Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US11021537B2 (en)	2017-05-01	2021-06-01	Agenus Inc.	Anti-TIGIT antibodies and methods of use thereof
AU2018265261A1 (en) *	2017-05-10	2019-12-05	Inovio Pharmaceuticals, Inc.	Optimized nucleic acid antibody constructs
CA3063362A1 (en)	2017-05-12	2018-11-15	Harpoon Therapeutics, Inc.	Msln targeting trispecific proteins and methods of use
JOP20190256A1 (ar)	2017-05-12	2019-10-28	Icahn School Med Mount Sinai	فيروسات داء نيوكاسل واستخداماتها
WO2018209298A1 (en)	2017-05-12	2018-11-15	Harpoon Therapeutics, Inc.	Mesothelin binding proteins
KR20200006985A (ko)	2017-05-12	2020-01-21	오거스타 유니버시티 리서치 인스티튜트, 인크.	인간 알파 태아단백-특이적 t 세포 수용체 및 이의 용도
US12168054B2 (en)	2017-05-19	2024-12-17	Syndax Pharmaceuticals, Inc.	Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
US12116406B2 (en)	2017-05-26	2024-10-15	Fred Hutchinson Cancer Center	Anti-CD33 antibodies and uses thereof
AU2018277545A1 (en)	2017-05-31	2019-12-19	Stcube & Co., Inc.	Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
JP7369038B2 (ja)	2017-05-31	2023-10-25	ストキューブアンドシーオー．，インコーポレイテッド	Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにその治療的使用
EP3409688A1 (en)	2017-05-31	2018-12-05	Tillotts Pharma Ag	Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
AU2018277294A1 (en)	2017-06-01	2019-12-05	Akamis Bio Limited	Oncolytic virus and method
TWI811220B (zh)	2017-06-02	2023-08-11	比利時商艾伯林克斯公司	結合聚集蛋白聚糖之免疫球蛋白
KR20200026209A (ko)	2017-06-06	2020-03-10	주식회사 에스티큐브앤컴퍼니	Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
WO2018232020A1 (en)	2017-06-13	2018-12-20	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
CN110945026B (zh)	2017-06-20	2024-03-19	特纳奥尼股份有限公司	仅有重链的抗bcma抗体
KR102742528B1 (ko)	2017-06-20	2024-12-16	테네오바이오, 인코포레이티드	항-bcma 중쇄-단독 항체
AR112257A1 (es)	2017-06-21	2019-10-09	Gilead Sciences Inc	Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos
US11613588B2 (en)	2017-06-28	2023-03-28	The Rockefeller University	Anti-mertk agonistic antibodies and uses thereof
WO2019018647A1 (en)	2017-07-20	2019-01-24	Pfizer Inc.	ANTI-GD3 ANTIBODIES AND CONJUGATES ANTIBODY-MEDICATION
EP3658581A1 (en)	2017-07-24	2020-06-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antibodies and peptides to treat hcmv related diseases
SG11202000634UA (en)	2017-07-27	2020-02-27	Nomocan Pharmaceuticals Llc	Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
WO2020159504A1 (en)	2019-01-30	2020-08-06	Nomocan Pharmaceuticals Llc	Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer
JP6889328B2 (ja) *	2017-07-31	2021-06-18	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	三次元構造に基づくヒト化方法
CN111565750B (zh)	2017-08-28	2023-11-03	安吉克公司	抗tm4sf1抗体及其使用方法
CN118909118A (zh)	2017-09-07	2024-11-08	奥古斯塔大学研究所公司	程序性细胞死亡蛋白1抗体
EP3456739A1 (en)	2017-09-19	2019-03-20	Tillotts Pharma Ag	Use of anti-tnfalpha antibodies for treating wounds
EP3459529A1 (en)	2017-09-20	2019-03-27	Tillotts Pharma Ag	Preparation of sustained release solid dosage forms comprising antibodies by spray drying
EP3459527B1 (en)	2017-09-20	2022-11-23	Tillotts Pharma Ag	Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
EP3459528B1 (en)	2017-09-20	2022-11-23	Tillotts Pharma Ag	Preparation of solid dosage forms comprising antibodies by solution/suspension layering
WO2019057933A1 (en)	2017-09-21	2019-03-28	Imcheck Therapeutics Sas	ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOF
WO2019070161A2 (en)	2017-10-04	2019-04-11	Opko Pharmaceuticals, Llc	ARTICLES AND METHODS FOR PERSONALIZED THERAPY OF CANCER
EP3694552A1 (en)	2017-10-10	2020-08-19	Tilos Therapeutics, Inc.	Anti-lap antibodies and uses thereof
US11332527B2 (en)	2017-10-12	2022-05-17	Keio University	Anti AQP3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (AQP3) and use thereof
IL315737A (en)	2017-10-13	2024-11-01	Harpoon Therapeutics Inc	B-cell maturation antigen-binding proteins
EP4435007A3 (en)	2017-10-13	2024-12-25	Harpoon Therapeutics, Inc.	Trispecific proteins and methods of use
PE20210119A1 (es)	2017-10-31	2021-01-19	Staten Biotechnology B V	Anticuerpos anti-apoc3 y metodos de uso de estos
TW201922294A (zh)	2017-10-31	2019-06-16	美商伊繆諾金公司	抗體-藥物結合物與阿糖胞苷之組合治療
CN111587123A (zh)	2017-11-09	2020-08-25	品通治疗有限公司	用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
BR112020008939A2 (pt)	2017-11-14	2020-10-20	Arcellx, Inc.	terapias de células imunes multifuncionais
WO2019102435A1 (en)	2017-11-27	2019-05-31	Euro-Celtique S.A.	Humanized antibodies targeting human tissue factor
KR20200104364A (ko)	2017-12-27	2020-09-03	테네오바이오, 인코포레이티드	Cd3-델타/엡실론 이형이량체 특이적 항체
GB201802486D0 (en)	2018-02-15	2018-04-04	Ucb Biopharma Sprl	Methods
AU2019225393A1 (en)	2018-02-23	2020-08-20	Cartherics Pty. Ltd.	T cell disease treatment targeting TAG-72
WO2019169229A1 (en)	2018-03-01	2019-09-06	Nextcure, Inc.	Klrg1 binding compositions and methods of use thereof
CN111819197B (zh)	2018-03-12	2025-03-11	硕腾服务有限责任公司	抗ngf抗体及其方法
GB201804701D0 (en)	2018-03-23	2018-05-09	Gammadelta Therapeutics Ltd	Lymphocytes expressing heterologous targeting constructs
JOP20200240A1 (ar)	2018-04-02	2020-09-27	Bristol Myers Squibb Co	أجسام مضادة ضد- trem-1 واستخداماتها
US20210228729A1 (en)	2018-04-12	2021-07-29	Mediapharma S.R.L.	Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
EP3784351A1 (en)	2018-04-27	2021-03-03	Novartis AG	Car t cell therapies with enhanced efficacy
WO2019207159A1 (en)	2018-04-27	2019-10-31	Fondazione Ebri Rita Levi-Montalcini	Antibody directed against a tau-derived neurotoxic peptide and uses thereof
EP3788369A1 (en)	2018-05-01	2021-03-10	Novartis Ag	Biomarkers for evaluating car-t cells to predict clinical outcome
KR20240056644A (ko)	2018-05-10	2024-04-30	주식회사 뉴라클사이언스	서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리 및 그의 사용 방법
WO2019222130A1 (en)	2018-05-15	2019-11-21	Immunogen, Inc.	Combination treatment with antibody-drug conjugates and flt3 inhibitors
CR20200563A (es)	2018-05-24	2021-05-11	Janssen Biotech Inc	Agentes aglutinantes de psma y usos de estos
US20210213063A1 (en)	2018-05-25	2021-07-15	Novartis Ag	Combination therapy with chimeric antigen receptor (car) therapies
EP3802611A2 (en)	2018-06-01	2021-04-14	Novartis AG	Binding molecules against bcma and uses thereof
WO2019236417A1 (en)	2018-06-04	2019-12-12	Biogen Ma Inc.	Anti-vla-4 antibodies having reduced effector function
DK3807316T3 (da)	2018-06-18	2024-07-29	Innate Pharma	Sammensætninger og fremgangsmåder til behandling af cancer
CA3102743A1 (en)	2018-06-18	2019-12-26	UCB Biopharma SRL	Gremlin-1 antagonist for the prevention and treatment of cancer
WO2019244107A1 (en)	2018-06-21	2019-12-26	Daiichi Sankyo Company, Limited	Compositions including cd3 antigen binding fragments and uses thereof
JP2021527693A (ja)	2018-06-21	2021-10-14	ユマニティセラピューティクス，インコーポレーテッド	神経学的障害の治療及び予防のための組成物及び方法
US11629179B2 (en)	2018-06-29	2023-04-18	Stichting Het Nederlands Kanker Instituut—Antoni van Leeuwenhoek Ziekenhuis	TWEAK-receptor agonists for use in combination with immunotherapy of a cancer
EP3841124A4 (en)	2018-06-29	2022-03-23	ApitBio, Inc.	ANTI-L1CAM ANTIBODIES AND THEIR USES
MX2021000324A (es)	2018-07-10	2021-03-25	Mitsubishi Tanabe Pharma Corp	Metodo de prevencion o tratamiento para neuropatia periferica o enfermedad acompa?ada por dolor en la que se reconoce la neuropatia periferica o trastorno de astrocitos.
CN112424231B (zh)	2018-07-19	2022-09-13	大有华夏生物医药集团有限公司	抗pd-1抗体及其剂量和用途
CN118994395A (zh)	2018-07-20	2024-11-22	皮埃尔法布雷医药公司	Vista受体
WO2020023561A1 (en)	2018-07-23	2020-01-30	Magenta Therapeutics, Inc.	Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
TW202026006A (zh)	2018-08-30	2020-07-16	美商Ｔｃｒ２療法股份有限公司	使用融合蛋白進行tcr再程式化之組成物及方法
WO2020056170A1 (en)	2018-09-12	2020-03-19	Fred Hutchinson Cancer Research Center	Reducing cd33 expression to selectively protect therapeutic cells
JP2022502076A (ja)	2018-09-18	2022-01-11	メリマックファーマシューティカルズインコーポレーティッド	抗ｔｎｆｒ２抗体およびその使用
US12240916B2 (en)	2018-09-21	2025-03-04	National Research Council Of Canada	Intrabodies for reducing FUT8 activity
WO2020061482A1 (en)	2018-09-21	2020-03-26	Harpoon Therapeutics, Inc.	Egfr binding proteins and methods of use
CN113286817B (zh)	2018-09-25	2025-01-28	哈普恩治疗公司	Dll3结合蛋白及使用方法
WO2020069405A1 (en)	2018-09-28	2020-04-02	Novartis Ag	Cd22 chimeric antigen receptor (car) therapies
CA3114295A1 (en)	2018-09-28	2020-04-02	Kyowa Kirin Co., Ltd.	Il-36 antibodies and uses thereof
EP3856782A1 (en)	2018-09-28	2021-08-04	Novartis AG	Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
CN112969503A (zh)	2018-10-03	2021-06-15	斯塔滕生物技术有限公司	对人类和食蟹猕猴apoc3具有特异性的抗体和其使用方法
TW202035445A (zh)	2018-10-10	2020-10-01	美商帝洛斯療法股份有限公司	抗lap抗體變異體及其用途
US20220144941A1 (en)	2018-10-16	2022-05-12	UCB Biopharma SRL	Method for the treatment of myasthenia gravis
GB201817311D0 (en)	2018-10-24	2018-12-05	Ucb Biopharma Sprl	Antibodies
GB201817309D0 (en)	2018-10-24	2018-12-05	Ucb Biopharma Sprl	Antibodies
WO2020086328A1 (en)	2018-10-25	2020-04-30	The Medical College Of Wisconsin, Inc.	Targeting clptm1l for treatment and prevention of cancer
US20220170097A1 (en)	2018-10-29	2022-06-02	The Broad Institute, Inc.	Car t cell transcriptional atlas
CN112930350A (zh)	2018-10-31	2021-06-08	尹图赛利有限公司	稠合杂环苯并二氮杂䓬衍生物及其用途
JP2022512860A (ja)	2018-11-06	2022-02-07	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	白血病幹細胞を根絶することによる急性骨髄性白血病の治療のための方法および医薬組成物
US20220026445A1 (en)	2018-12-07	2022-01-27	Georgia Tech Research Corporation	Antibodies that bind to natively folded myocilin
WO2020114616A1 (en)	2018-12-07	2020-06-11	Tillotts Pharma Ag	Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
KR102762828B1 (ko)	2018-12-11	2025-02-05	큐32 바이오 인크.	보체 연관 질환을 위한 융합 단백질 작제물
WO2020120786A1 (en)	2018-12-14	2020-06-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
WO2020128927A1 (en)	2018-12-20	2020-06-25	Kyowa Kirin Co., Ltd.	Fn14 antibodies and uses thereof
GB201900732D0 (en)	2019-01-18	2019-03-06	Ucb Biopharma Sprl	Antibodies
KR20210122243A (ko)	2019-01-31	2021-10-08	누맙 세러퓨틱스 아게	ＴＮＦα 및 ＩＬ-17Ａ에 대한 특이성을 가지는 다중 특이적 항체, ＩＬ-17Ａ를 표적화하는 항체, 그리고 이의 사용 방법
AU2020218446B2 (en)	2019-02-04	2023-05-25	National University Corporation Ehime University	"CAR LIBRARY AND scFv MANUFACTURING METHOD
WO2020169472A2 (en)	2019-02-18	2020-08-27	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of inducing phenotypic changes in macrophages
US20220098307A1 (en)	2019-02-22	2022-03-31	Wuhan Yzy Biopharma Co., Ltd.	Modified fc fragment, antibody comprising same, and application thereof
EP3928790A4 (en)	2019-02-22	2023-01-11	Wuhan Yzy Biopharma Co., Ltd.	Cd3 antigen binding fragment and application thereof
US20220088075A1 (en)	2019-02-22	2022-03-24	The Trustees Of The University Of Pennsylvania	Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
WO2020176497A1 (en)	2019-02-26	2020-09-03	Rgenix, Inc.	High-affinity anti-mertk antibodies and uses thereof
WO2020180712A1 (en)	2019-03-01	2020-09-10	Merrimack Pharmaceuticals, Inc.	Anti-tnfr2 antibodies and uses thereof
EP3938400A4 (en)	2019-03-11	2022-11-23	Memorial Sloan Kettering Cancer Center	Cd22 antibodies and methods of using the same
US12258400B2 (en)	2019-03-20	2025-03-25	Imcheck Therapeutics Sas	Antibodies having specificity for BTN2 and uses thereof
CN113631573B (zh)	2019-03-25	2024-06-04	国家医疗保健研究所	抗Tau抗体及其在制备用于治疗疾病的药物中的用途
JP2022528324A (ja)	2019-03-26	2022-06-10	アスランファーマシューティカルズピーティーイーリミテッド	抗ｉｌ１３ｒ抗体またはその結合フラグメントを用いた治療
WO2020198731A2 (en)	2019-03-28	2020-10-01	Danisco Us Inc	Engineered antibodies
WO2020206330A1 (en)	2019-04-05	2020-10-08	Teneobio, Inc.	Heavy chain antibodies binding to psma
WO2020213084A1 (en)	2019-04-17	2020-10-22	Keio University	Anti aqp3 monoclonal antibody specifically binding to extracellular domain of aquaporin 3 (aqp3) and use thereof
WO2020236792A1 (en)	2019-05-21	2020-11-26	Novartis Ag	Cd19 binding molecules and uses thereof
EP3972993A1 (en)	2019-05-21	2022-03-30	Novartis AG	Variant cd58 domains and uses thereof
CN113874073A (zh)	2019-05-23	2021-12-31	詹森生物科技公司	用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
JP2022537931A (ja)	2019-06-14	2022-08-31	テネオバイオ，インコーポレイテッド	Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
US20220257796A1 (en)	2019-07-02	2022-08-18	Fred Hutchinson Cancer Research Center	Recombinant ad35 vectors and related gene therapy improvements
WO2021003739A1 (zh)	2019-07-11	2021-01-14	武汉友芝友生物制药有限公司	四价对称双特异性抗体
EP4004050A2 (en)	2019-07-30	2022-06-01	QLSF Biotherapeutics Inc.	Multispecific binding compound that bind to lfrrc15 and cd3
JP2022543259A (ja)	2019-08-02	2022-10-11	オレガ・バイオテック	新規ｉｌ－１７ｂ抗体
BR112022002761A2 (pt)	2019-08-12	2022-08-09	Aptevo Res & Development Llc	Proteínas de ligação a 4-1bb e ox40 e composições e métodos relacionados, anticorpos contra 4-1bb, anticorpos contra ox40
CN114450027A (zh)	2019-08-16	2022-05-06	儿童医院医疗中心	用cdc42特异性抑制剂治疗受试者的方法
WO2021035170A1 (en)	2019-08-21	2021-02-25	Precision Biosciences, Inc.	Compositions and methods for tcr reprogramming using fusion proteins
KR20220053007A (ko)	2019-08-30	2022-04-28	아게누스 인코포레이티드	항-cd96 항체 및 이의 사용 방법
JP7628111B2 (ja)	2019-09-03	2025-02-07	バイオ－テラソリューションズ、リミテッド	抗ｔｉｇｉｔ免疫阻害剤及び応用
CN114729045A (zh)	2019-09-26	2022-07-08	斯特库比公司	对糖基化的ctla-4特异性的抗体及其使用方法
WO2021058729A1 (en)	2019-09-27	2021-04-01	INSERM (Institut National de la Santé et de la Recherche Médicale)	Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
CN114450304B (zh)	2019-09-27	2023-12-12	国家医疗保健研究所	抗苗勒管抑制物质抗体及其用途
WO2021072277A1 (en)	2019-10-09	2021-04-15	Stcube & Co.	Antibodies specific to glycosylated lag3 and methods of use thereof
EP3812008A1 (en)	2019-10-23	2021-04-28	Gamamabs Pharma	Amh-competitive antagonist antibody
EP3825330A1 (en)	2019-11-19	2021-05-26	International-Drug-Development-Biotech	Anti-cd117 antibodies and methods of use thereof
EP4061944A1 (en)	2019-11-22	2022-09-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
GB201917480D0 (en)	2019-11-29	2020-01-15	Univ Oxford Innovation Ltd	Antibodies
US11897950B2 (en)	2019-12-06	2024-02-13	Augusta University Research Institute, Inc.	Osteopontin monoclonal antibodies
EP4072682A1 (en)	2019-12-09	2022-10-19	Institut National de la Santé et de la Recherche Médicale (INSERM)	Antibodies having specificity to her4 and uses thereof
US20230227559A1 (en)	2019-12-10	2023-07-20	Institut Pasteur	New antibody blocking human fcgriiia and fcgriiib
GB201919058D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibodies
GB201919062D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Antibody
GB201919061D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibody
AR120898A1 (es)	2019-12-26	2022-03-30	Univ Osaka	Agente para tratar o prevenir neuromielitis óptica en fase aguda
BR112022012885A2 (pt)	2019-12-30	2022-09-06	Seagen Inc	Método para tratar um câncer que expressa cd70 em um sujeito, composição farmacêutica para o tratamento de um câncer que expressa cd70, e, kit
US20230090552A1 (en)	2020-01-08	2023-03-23	Synthis Therapeutics, Inc.	Alk5 inhibitor conjugates and uses thereof
KR20220113794A (ko)	2020-01-15	2022-08-16	고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸	치매증의 예방 또는 치료제
CN118767130A (zh)	2020-01-15	2024-10-15	国立大学法人大阪大学	糖尿病性自主神经障碍的预防或治疗剂
GB202001447D0 (en)	2020-02-03	2020-03-18	Ucb Biopharma Sprl	Antibodies
IL295387A (en)	2020-02-05	2022-10-01	Larimar Therapeutics Inc	Tat peptide binding proteins and uses thereof
US20230096030A1 (en)	2020-02-13	2023-03-30	UCB Biopharma SRL	Bispecific antibodies against cd9 and cd7
US20230151109A1 (en)	2020-02-13	2023-05-18	UCB Biopharma SRL	Bispecific antibodies against cd9
US20230151108A1 (en)	2020-02-13	2023-05-18	UCB Biopharma SRL	Bispecific antibodies against cd9 and cd137
EP4103610A1 (en)	2020-02-13	2022-12-21	UCB Biopharma SRL	Anti cd44-ctla4 bispecific antibodies
US20230192900A1 (en)	2020-02-13	2023-06-22	UCB Biopharma SRL	Bispecific antibodies binding hvem and cd9
JP2023527609A (ja)	2020-02-21	2023-06-30	ハープーンセラピューティクス，インク．	Ｆｌｔ３結合タンパク質および使用方法
EP4110404A1 (en)	2020-02-28	2023-01-04	Genzyme Corporation	Modified binding polypeptides for optimized drug conjugation
WO2021175954A1 (en)	2020-03-04	2021-09-10	Imcheck Therapeutics Sas	Antibodies having specificity for btnl8 and uses thereof
CA3174103A1 (en)	2020-03-06	2021-09-10	Go Therapeutics, Inc.	Anti-glyco-cd44 antibodies and their uses
CA3173981A1 (en)	2020-03-10	2021-09-16	Massachusetts Institute Of Technology	Compositions and methods for immunotherapy of npm1c-positive cancer
US20230203191A1 (en)	2020-03-30	2023-06-29	Danisco Us Inc	Engineered antibodies
WO2021197340A1 (zh)	2020-03-31	2021-10-07	百奥泰生物制药股份有限公司	用于治疗冠状病毒的抗体、融合蛋白及其应用
EP4132971A1 (en)	2020-04-09	2023-02-15	Merck Sharp & Dohme LLC	Affinity matured anti-lap antibodies and uses thereof
MX2022013402A (es)	2020-04-24	2022-11-14	Sanofi Sa	Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y folfiri.
US20230151088A1 (en)	2020-04-24	2023-05-18	Sanofi	Antitumor combinations containing anti-ceacam5 antibody conjugates and folfox
JP2023522396A (ja)	2020-04-24	2023-05-30	サノフイ	抗ｃｅａｃａｍ５抗体コンジュゲート、トリフルリジン、およびチピラシルを含有する抗腫瘍組み合わせ
CA3180872A1 (en)	2020-04-24	2021-10-28	Sanofi	Antitumor combinations containing anti-ceacam5 antibody conjugates and cetuximab
CN113637082A (zh)	2020-04-27	2021-11-12	启愈生物技术(上海)有限公司	一种靶向人claudin和人PDL1蛋白的双特异抗体及其应用
AU2021263448A1 (en)	2020-04-29	2022-11-24	Teneobio, Inc.	Multispecific heavy chain antibodies with modified heavy chain constant regions
EP4149558A1 (en)	2020-05-12	2023-03-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
US12258393B2 (en)	2020-05-21	2025-03-25	Janssen Biotech, Inc.	Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
EP3915641A1 (en)	2020-05-27	2021-12-01	International-Drug-Development-Biotech	Anti-cd5 antibodies and methods of use thereof
KR20230024967A (ko)	2020-06-11	2023-02-21	노파르티스 아게	Zbtb32 억제제 및 이의 용도
AU2021292511A1 (en)	2020-06-17	2023-02-16	Janssen Biotech, Inc.	Materials and methods for the manufacture of pluripotent stem cells
US12077576B2 (en)	2020-07-02	2024-09-03	Trustees Of Tufts College	VHH polypeptides that bind to Clostridium difficile toxin b and methods of use thereof
JPWO2022014703A1 (fi)	2020-07-17	2022-01-20
US12134658B2 (en)	2020-08-03	2024-11-05	Janssen Biotech, Inc.	Materials and methods for multidirectional biotransportation in virotherapeutics
JP2023537022A (ja)	2020-08-07	2023-08-30	バイオ－テラソリュ－ションズ，エルティーディー．	抗ｐｄ－ｌ１抗体及びその応用
IL301004A (en)	2020-09-04	2023-04-01	Merck Patent Gmbh	Anti-ceacam5 antibodies and conjugates and uses thereof
JP2023544839A (ja)	2020-10-07	2023-10-25	ゾエティス・サービシーズ・エルエルシー	抗ｎｇｆ抗体及びその使用方法
EP3981789A1 (en)	2020-10-12	2022-04-13	Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives	Anti-lilrb antibodies and uses thereof
IL301859A (en)	2020-10-15	2023-06-01	UCB Biopharma SRL	Binding molecules that multimerise cd45
WO2022081436A1 (en)	2020-10-15	2022-04-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
JP2023545447A (ja)	2020-10-16	2023-10-30	キューエルエスエフバイオセラピューティクス，インコーポレイテッド	Ｐｄ－ｌ１に結合する多重特異性結合化合物
WO2022087274A1 (en)	2020-10-21	2022-04-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies that neutralize type-i interferon (ifn) activity
CA3197465A1 (en)	2020-11-02	2022-05-05	UCB Biopharma SRL	Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
WO2022097060A1 (en)	2020-11-06	2022-05-12	Novartis Ag	Cd19 binding molecules and uses thereof
EP4240494A1 (en)	2020-11-06	2023-09-13	Novartis AG	Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
WO2022095970A1 (zh)	2020-11-06	2022-05-12	百奥泰生物制药股份有限公司	双特异抗体及其应用
AU2021378316A1 (en)	2020-11-13	2023-06-01	Novartis Ag	Combination therapies with chimeric antigen receptor (car)-expressing cells
EP4247829A1 (en)	2020-11-20	2023-09-27	R.P. Scherer Technologies, LLC	Glycoside dual-cleavage linkers for antibody-drug conjugates
CA3200314A1 (en)	2020-12-01	2022-06-09	Peter Pavlik	Tumor-associated antigens and cd-3 binding proteins, related compositions, and methods
AU2021398385A1 (en)	2020-12-07	2023-07-13	UCB Biopharma SRL	Antibodies against interleukin-22
AR125581A1 (es)	2020-12-07	2023-08-02	UCB Biopharma SRL	Anticuerpos multiespecíficos y combinaciones de anticuerpos
TW202237638A (zh)	2020-12-09	2022-10-01	日商武田藥品工業股份有限公司	烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh)	2020-12-09	2022-10-01	日商武田藥品工業股份有限公司	鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
US20240092892A1 (en)	2020-12-30	2024-03-21	Bio-Thera Solutions, Ltd.	Anti-cldn18.2 antibody, and preparation method therefor and use thereof
WO2022148736A1 (en)	2021-01-05	2022-07-14	Transgene	Vectorization of muc1 t cell engager
TW202237135A (zh)	2021-01-13	2022-10-01	紀念斯隆凱特琳癌症中心	抗體-吡咯并苯并二氮呯衍生物結合物
US20240115721A1 (en)	2021-01-13	2024-04-11	Memorial Sloan Kettering Cancer Center	Anti-dll3 antibody-drug conjugate
WO2022159575A1 (en)	2021-01-20	2022-07-28	Bioentre Llc	Ctla4-binding proteins and methods of treating cancer
AR124681A1 (es)	2021-01-20	2023-04-26	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
US20240101673A1 (en)	2021-02-03	2024-03-28	Mozart Therapeutics, Inc.	Binding agents and methods of using the same
WO2022186773A1 (en)	2021-03-01	2022-09-09	Aslan Pharmaceuticals Pte Ltd	TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
WO2022186772A1 (en)	2021-03-01	2022-09-09	Aslan Pharmaceuticals Pte Ltd	TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
JP2024508157A (ja)	2021-03-04	2024-02-22	センターナショナルデラレシェルシェサイエンティフィーク	炎症、線維症及び肺疾患を治療するためのペリオスチン抗体の使用
JP2024512324A (ja)	2021-03-05	2024-03-19	ジーオーセラピューティクス，インコーポレイテッド	抗グリコｃｄ４４抗体およびその使用
AU2022238849A1 (en)	2021-03-17	2023-08-31	Receptos Llc	Methods of treating atopic dermatitis with anti il-13 antibodies
WO2022201122A1 (en)	2021-03-26	2022-09-29	Janssen Biotech, Inc.	Humanized antibodies against paired helical filament tau and uses thereof
EP4067381A1 (en)	2021-04-01	2022-10-05	Julius-Maximilians-Universität Würzburg	Novel tnfr2 binding molecules
EP4314068A1 (en)	2021-04-02	2024-02-07	The Regents Of The University Of California	Antibodies against cleaved cdcp1 and uses thereof
US20240254224A1 (en)	2021-05-03	2024-08-01	UCB Biopharma SRL	Antibodies
JP2024517844A (ja)	2021-05-04	2024-04-23	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	多重特異性ｆｇｆ２１受容体アゴニスト及びそれらの使用
EP4334354A1 (en)	2021-05-06	2024-03-13	Dana-Farber Cancer Institute, Inc.	Antibodies against alk and methods of use thereof
IL309349A (en)	2021-06-14	2024-02-01	argenx BV	Antibodies against interleukin 9 and methods of using them
WO2022263507A1 (en)	2021-06-17	2022-12-22	Boehringer Ingelheim International Gmbh	Novel tri-specific binding molecules
WO2022269473A1 (en)	2021-06-23	2022-12-29	Janssen Biotech, Inc.	Materials and methods for hinge regions in functional exogenous receptors
CA3221281A1 (en)	2021-06-29	2023-01-05	Seagen Inc.	Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
JP2024528029A (ja)	2021-07-29	2024-07-26	武田薬品工業株式会社	メソテリンを特異的に標的とする操作された免疫細胞及びその使用
KR20240095160A (ko)	2021-07-29	2024-06-25	인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸)	인간화된 항-인간 βig-h3 단백질 및 이의 용도
KR20240107093A (ko)	2021-08-05	2024-07-08	고 테라퓨틱스, 인크.	항-글리코-muc4 항체 및 그의 용도
CN118019548A (zh)	2021-08-06	2024-05-10	蒙彼利埃癌症研究所	用于治疗癌症的方法
AU2022325950A1 (en)	2021-08-11	2024-02-22	Viela Bio, Inc.	Inebilizumab and methods of using the same in the treatment or prevention of igg4-related disease
GB202111905D0 (en)	2021-08-19	2021-10-06	UCB Biopharma SRL	Antibodies
CA3230934A1 (en)	2021-09-03	2023-03-09	Go Therapeutics, Inc.	Anti-glyco-cmet antibodies and their uses
US20250066498A1 (en)	2021-09-03	2025-02-27	Go Therapeutics, Inc.	Anti-glyco-lamp1 antibodies and their uses
WO2023048650A1 (en)	2021-09-27	2023-03-30	Aslan Pharmaceuticals Pte Ltd	TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2023048651A1 (en)	2021-09-27	2023-03-30	Aslan Pharmaceuticals Pte Ltd	Method for treatment of moderate to severe atoptic dematitis
WO2023051663A1 (zh)	2021-09-30	2023-04-06	百奥泰生物制药股份有限公司	抗b7-h3抗体及其应用
WO2023056069A1 (en)	2021-09-30	2023-04-06	Angiex, Inc.	Degrader-antibody conjugates and methods of using same
GB202115122D0 (en)	2021-10-21	2021-12-08	Dualyx Nv	Binding molecules targeting IL-2 receptor
WO2023076876A1 (en)	2021-10-26	2023-05-04	Mozart Therapeutics, Inc.	Modulation of immune responses to viral vectors
TW202333784A (zh)	2021-10-29	2023-09-01	新加坡商亞獅康私人有限公司	抗ｉｌ１３ｒ抗體調配物
EP4426736A1 (en)	2021-11-05	2024-09-11	Sanofi	Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
CA3238936A1 (en)	2021-11-24	2023-06-01	Wayne A. Marasco	Antibodies against ctla-4 and methods of use thereof
CA3241395A1 (en)	2021-12-17	2023-06-22	Barbel SCHROFELBAUER	Antibodies and uses thereof
CA3241407A1 (en)	2021-12-17	2023-06-22	Dana-Farber Cancer Institute, Inc.	Platform for antibody discovery
EP4455164A1 (en)	2021-12-24	2024-10-30	Bio-Thera Solutions, Ltd.	ANTI-FRalpha ANTIBODY, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
AU2023206045A1 (en)	2022-01-07	2024-08-22	Johnson & Johnson Enterprise Innovation Inc.	Materials and methods of il-1beta binding proteins.
WO2023140780A1 (en)	2022-01-24	2023-07-27	Aslan Pharmaceuticals Pte Ltd.	Method of treating inflammatory disease
CN118984837A (zh)	2022-01-28	2024-11-19	乔治穆内公司	作为pd-1激动剂的程序性细胞死亡蛋白1的抗体
TW202337905A (zh)	2022-02-23	2023-10-01	新加坡商亞獅康私人有限公司	抗il13r抗體之糖基化形式
IL315397A (en)	2022-03-09	2024-11-01	Merck Patent Gmbh	Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
AU2023232411A1 (en)	2022-03-09	2024-10-24	Merck Patent Gmbh	Anti-ceacam5 antibodies and conjugates and uses thereof
CN119173532A (zh)	2022-03-11	2024-12-20	詹森药业有限公司	多特异性抗体及其用途
IL315541A (en)	2022-03-11	2024-11-01	Janssen Pharmaceutica Nv	Multispecific antibodies and their uses
AU2023232448A1 (en)	2022-03-11	2024-10-24	Janssen Pharmaceutica Nv	Multispecific antibodies and uses thereof
EP4245772A1 (en)	2022-03-18	2023-09-20	Netris Pharma	Anti-netrin-1 antibody to treat liver inflammation
EP4249509A1 (en)	2022-03-22	2023-09-27	Netris Pharma	Anti-netrin-1 antibody against arthritis-associated pain
EP4499687A1 (en)	2022-03-29	2025-02-05	Netris Pharma	Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
GB202205200D0 (en)	2022-04-08	2022-05-25	Ucb Biopharma Sprl	Combination with chemotherapy
GB202205203D0 (en)	2022-04-08	2022-05-25	UCB Biopharma SRL	Combination with inhibitor
WO2023215498A2 (en)	2022-05-05	2023-11-09	Modernatx, Inc.	Compositions and methods for cd28 antagonism
WO2023232080A1 (zh)	2022-06-01	2023-12-07	百奥泰生物制药股份有限公司	抗cldn18.2抗体及其抗体药物偶联物和用途
WO2023239803A1 (en)	2022-06-08	2023-12-14	Angiex, Inc.	Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
WO2023240287A1 (en)	2022-06-10	2023-12-14	Bioentre Llc	Combinations of ctla4 binding proteins and methods of treating cancer
WO2024015953A1 (en)	2022-07-15	2024-01-18	Danisco Us Inc.	Methods for producing monoclonal antibodies
WO2024013727A1 (en)	2022-07-15	2024-01-18	Janssen Biotech, Inc.	Material and methods for improved bioengineered pairing of antigen-binding variable regions
GB202210679D0 (en)	2022-07-21	2022-09-07	Dualyx Nv	Binding molecules targeting il-12rb2
GB202210680D0 (en)	2022-07-21	2022-09-07	Dualyx Nv	Binding molecules targeting il-35r
WO2024018426A1 (en)	2022-07-22	2024-01-25	Janssen Biotech, Inc.	Enhanced transfer of genetic instructions to effector immune cells
WO2024039672A2 (en)	2022-08-15	2024-02-22	Dana-Farber Cancer Institute, Inc.	Antibodies against msln and methods of use thereof
AU2023324667A1 (en)	2022-08-15	2025-02-13	Dana-Farber Cancer Institute, Inc.	Antibodies against cldn4 and methods of use thereof
WO2024043837A1 (en)	2022-08-26	2024-02-29	Aslan Pharmaceuticals Pte Ltd	High concentration anti-il13r antibody formulation
WO2024050354A1 (en)	2022-08-31	2024-03-07	Washington University	Alphavirus antigen binding antibodies and uses thereof
WO2024050524A1 (en)	2022-09-01	2024-03-07	University Of Georgia Research Foundation, Inc.	Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
WO2024054157A1 (en)	2022-09-06	2024-03-14	Aslan Pharmaceuticals Pte Ltd	Treatment for sleep loss or sleep disturbance in patients with dermatitis
WO2024056668A1 (en)	2022-09-12	2024-03-21	Institut National de la Santé et de la Recherche Médicale	New anti-itgb8 antibodies and its uses thereof
WO2024056861A1 (en)	2022-09-15	2024-03-21	Avidicure Ip B.V.	Multispecific antigen binding proteins for stimulating nk cells and use thereof
WO2024062072A2 (en)	2022-09-21	2024-03-28	Domain Therapeutics	Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062076A1 (en)	2022-09-21	2024-03-28	Domain Therapeutics	Anti-ccr8 monoclonal antibodies and their therapeutic use
WO2024062082A1 (en)	2022-09-21	2024-03-28	Domain Therapeutics	Anti-ccr8 monoclonal antibodies and their therapeutic use
GB202214132D0 (en)	2022-09-27	2022-11-09	Coding Bio Ltd	CLL1 binding molecules
WO2024068996A1 (en)	2022-09-30	2024-04-04	Centre Hospitalier Universitaire Vaudois (C.H.U.V.)	Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
EP4353253A1 (en)	2022-10-10	2024-04-17	Charité - Universitätsmedizin Berlin	Purification of tcr-modified t cells using tcr-specific car-nk cells
WO2024097639A1 (en)	2022-10-31	2024-05-10	Modernatx, Inc.	Hsa-binding antibodies and binding proteins and uses thereof
WO2024115393A1 (en)	2022-11-28	2024-06-06	UCB Biopharma SRL	Treatment of fibromyalgia
GB202217923D0 (en)	2022-11-29	2023-01-11	Univ Oxford Innovation Ltd	Antibodies
WO2024118866A1 (en)	2022-12-01	2024-06-06	Modernatx, Inc.	Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024133052A1 (en)	2022-12-19	2024-06-27	Universität Basel Vizerektorat Forschung	T-cell receptor fusion protein
WO2024133858A1 (en)	2022-12-22	2024-06-27	Julius-Maximilians-Universität-Würzburg	Antibodies for use as coagulants
WO2024138144A1 (en) *	2022-12-22	2024-06-27	The Medical College Of Wisconsin, Inc.	Compositions that target cd138 and cd3 and methods of making and using the same
WO2024152014A1 (en)	2023-01-13	2024-07-18	Regeneron Pharmaceuticals, Inc.	Fgfr3 binding molecules and methods of use thereof
WO2024167898A1 (en)	2023-02-07	2024-08-15	Go Therapeutics, Inc.	ANTIBODY FUSION PROTEINS COMPRISING ANTI-GLYCO-MUC4 ANTIBODIES AND MIC PROTEIN α1-α2 DOMAINS, AND THEIR USES
GB202301949D0 (en)	2023-02-10	2023-03-29	Coding Bio Ltd	CLL1 and/or CD33 binding molecules
WO2024178305A1 (en)	2023-02-24	2024-08-29	Modernatx, Inc.	Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
WO2024180085A1 (en)	2023-02-27	2024-09-06	Netris Pharma	Anti-netrin-1 monoclonal antibody for treating endometriosis and associated pains
WO2024180192A1 (en)	2023-03-01	2024-09-06	Sanofi	Use of anti-ceacam5 immunoconjugates for treating neuroendocrine cancers expressing ceacam5
EP4427763A1 (en)	2023-03-06	2024-09-11	Sanofi	Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
EP4431526A1 (en)	2023-03-16	2024-09-18	Emfret Analytics GmbH & Co. KG	Anti-gpvi antibodies and functional fragments thereof
WO2024188356A1 (en)	2023-03-16	2024-09-19	Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd.	Ilt7-targeting antibodies and uses thereof
WO2024194685A2 (en)	2023-03-17	2024-09-26	Oxitope Pharma B.V.	Anti-phosphocholine antibodies and methods of use thereof
WO2024194686A2 (en)	2023-03-17	2024-09-26	Oxitope Pharma B.V.	Anti-phosphocholine antibodies and methods of use thereof
WO2024194455A1 (en)	2023-03-23	2024-09-26	Sanofi	CEACAM5 mRNA ASSAY FOR PATIENT SELECTION IN CANCER THERAPY
WO2024206126A1 (en)	2023-03-27	2024-10-03	Modernatx, Inc.	Cd16-binding antibodies and uses thereof
WO2024206329A1 (en)	2023-03-27	2024-10-03	Modernatx, Inc.	Nucleic acid molecules encoding bi-specific secreted engagers and uses thereof
WO2024200722A1 (en)	2023-03-28	2024-10-03	Tillotts Pharma Ag	Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract
WO2024209089A1 (en)	2023-04-07	2024-10-10	Commissariat A L'energie Atomique Et Aux Energies Alternatives	Use of antibody against the endothelin receptor b for diagnostic and therapeutic applications
WO2024251733A1 (en)	2023-06-05	2024-12-12	Sanofi	Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-pd1/pd-l1 antibodies and anti-ctla4 antibodies
WO2024258967A1 (en)	2023-06-13	2024-12-19	Synthis Therapeutics, Inc.	Anti-cd5 antibodies and their uses
WO2024259305A1 (en)	2023-06-14	2024-12-19	The Broad Institute, Inc.	Vhh polypeptides that bind to mesothelin, compositions and methods of use thereof
WO2024261239A1 (en)	2023-06-23	2024-12-26	Imcheck Therapeutics	Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
WO2025012417A1 (en)	2023-07-13	2025-01-16	Institut National de la Santé et de la Recherche Médicale	Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025027529A1 (en)	2023-07-31	2025-02-06	Advesya	Anti-il-1rap antibody drug conjugates and methods of use thereof
WO2025032158A1 (en)	2023-08-08	2025-02-13	Institut National de la Santé et de la Recherche Médicale	Method to treat tauopathies
WO2025049272A1 (en)	2023-08-25	2025-03-06	The Broad Institute, Inc.	Card9 variant polypeptide and antibodies directed thereto

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4348376A (en)	1980-03-03	1982-09-07	Goldenberg Milton David	Tumor localization and therapy with labeled anti-CEA antibody
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4695459A (en) *	1984-12-26	1987-09-22	The Board Of Trustees Of Leland Stanford Junior University	Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
US5618920A (en) *	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) *	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
GB8720833D0 (en) *	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
AU625613B2 (en) *	1988-01-05	1992-07-16	Novartis Ag	Novel chimeric antibodies
JP3121823B2 (ja) *	1988-02-12	2001-01-09	ビーティージー・インターナショナル・リミテッド	抗体におけるまたは抗体に関する改良
EP0365209A3 (en) *	1988-10-17	1990-07-25	Becton, Dickinson and Company	Anti-leu 3a amino acid sequence
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2018248A1 (en) *	1989-06-07	1990-12-07	Clyde W. Shearman	Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US5062934A (en) *	1989-12-18	1991-11-05	Oronzio Denora S.A.	Method and apparatus for cathodic protection
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US6750325B1 (en)	1989-12-21	2004-06-15	Celltech R&D Limited	CD3 specific recombinant antibody
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB9014932D0 (en) *	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
GB9019812D0 (en) *	1990-09-11	1990-10-24	Scotgen Ltd	Novel antibodies for treatment and prevention of infection in animals and man
GB9021679D0 (en) *	1990-10-05	1990-11-21	Gorman Scott David	Antibody preparation
US5994510A (en)	1990-12-21	1999-11-30	Celltech Therapeutics Limited	Recombinant antibodies specific for TNFα
WO1992015683A1 (en) *	1991-03-06	1992-09-17	MERCK Patent Gesellschaft mit beschränkter Haftung	Humanized and chimeric monoclonal antibodies
EP1681305A3 (en) *	1991-03-18	2008-02-27	New York University	Monoclonal and chimeric antibodies specific for human tumor necrosis factor
JPH06202412A (ja) *	1992-12-26	1994-07-22	Canon Inc	画像形成装置
US6180377B1 (en) *	1993-06-16	2001-01-30	Celltech Therapeutics Limited	Humanized antibodies
US5535089A (en) *	1994-10-17	1996-07-09	Jing Mei Industrial Holdings, Ltd.	Ionizer

1989
- 1989-12-21 GB GB898928874A patent/GB8928874D0/en active Pending
1990
- 1990-12-21 BR BR909007197A patent/BR9007197A/pt unknown
- 1990-12-21 EP EP91901835A patent/EP0460178B1/en not_active Expired - Lifetime
- 1990-12-21 KR KR1019910700944A patent/KR100191152B1/ko not_active IP Right Cessation
- 1990-12-21 AU AU70486/91A patent/AU631481B2/en not_active Expired
- 1990-12-21 CA CA002046904A patent/CA2046904C/en not_active Expired - Lifetime
- 1990-12-21 ES ES94202090T patent/ES2165864T3/es not_active Expired - Lifetime
- 1990-12-21 DK DK91901559.4T patent/DK0460171T3/da active
- 1990-12-21 RO RO148283A patent/RO114980B1/ro unknown
- 1990-12-21 AT AT91901835T patent/ATE159299T1/de not_active IP Right Cessation
- 1990-12-21 CA CA002050479A patent/CA2050479C/en not_active Expired - Lifetime
- 1990-12-21 DE DE69033857T patent/DE69033857T2/de not_active Revoked
- 1990-12-21 EP EP94104042A patent/EP0620276A1/en not_active Withdrawn
- 1990-12-21 JP JP3501864A patent/JPH04505398A/ja active Pending
- 1990-12-21 RO RO148281A patent/RO114232B1/ro unknown
- 1990-12-21 ES ES91901433T patent/ES2079638T3/es not_active Expired - Lifetime
- 1990-12-21 DK DK91901433.2T patent/DK0460167T3/da active
- 1990-12-21 HU HU734/91A patent/HU215383B/hu unknown
- 1990-12-21 DE DE69031591T patent/DE69031591T2/de not_active Expired - Lifetime
- 1990-12-21 AT AT91901433T patent/ATE129017T1/de not_active IP Right Cessation
- 1990-12-21 AU AU70330/91A patent/AU649645B2/en not_active Expired
- 1990-12-21 HU HU912751A patent/HUT60786A/hu unknown
- 1990-12-21 AU AU69740/91A patent/AU646009B2/en not_active Expired
- 1990-12-21 RU SU5001870A patent/RU2112037C1/ru active
- 1990-12-21 WO PCT/GB1990/002017 patent/WO1991009967A1/en not_active Application Discontinuation
- 1990-12-21 DK DK94202090T patent/DK0626390T3/da active
- 1990-12-21 DE DE69020544T patent/DE69020544T2/de not_active Expired - Lifetime
- 1990-12-21 JP JP50210791A patent/JP3452062B2/ja not_active Expired - Lifetime
- 1990-12-21 HU HU912734A patent/HUT58372A/hu unknown
- 1990-12-21 KR KR1019910700949A patent/KR100197956B1/ko not_active Expired - Lifetime
- 1990-12-21 JP JP50186591A patent/JP3242913B2/ja not_active Expired - Lifetime
- 1990-12-21 HU HU752/91A patent/HU217693B/hu unknown
- 1990-12-21 DE DE69022982T patent/DE69022982T2/de not_active Revoked
- 1990-12-21 RO RO148282A patent/RO114298B1/ro unknown
- 1990-12-21 EP EP91901433A patent/EP0460167B1/en not_active Revoked
- 1990-12-21 AT AT94202090T patent/ATE208794T1/de not_active IP Right Cessation
- 1990-12-21 WO PCT/GB1990/002015 patent/WO1991009966A1/en active IP Right Grant
- 1990-12-21 DK DK91901835.8T patent/DK0460178T3/da active
- 1990-12-21 ES ES91901835T patent/ES2112270T3/es not_active Expired - Lifetime
- 1990-12-21 ES ES91901559T patent/ES2074701T3/es not_active Expired - Lifetime
- 1990-12-21 WO PCT/GB1990/002018 patent/WO1991009968A1/en active IP Right Grant
- 1990-12-21 EP EP94202090A patent/EP0626390B1/en not_active Revoked
- 1990-12-21 AT AT91901559T patent/ATE124459T1/de not_active IP Right Cessation
- 1990-12-21 EP EP91901559A patent/EP0460171B1/en not_active Expired - Lifetime
1991
- 1991-03-06 CA CA002037607A patent/CA2037607C/en not_active Expired - Lifetime
- 1991-08-15 GB GB9117612A patent/GB2246570B/en not_active Expired - Lifetime
- 1991-08-15 GB GB9117611A patent/GB2246781B/en not_active Revoked
- 1991-08-19 NO NO91913229A patent/NO913229L/no not_active Application Discontinuation
- 1991-08-19 NO NO19913228A patent/NO316076B1/no not_active IP Right Cessation
- 1991-08-20 NO NO19913271A patent/NO310560B1/no not_active IP Right Cessation
- 1991-08-20 FI FI913926A patent/FI108777B/fi active
- 1991-08-20 FI FI913932A patent/FI108917B/fi active
- 1991-08-20 KR KR1019910700950A patent/KR100198478B1/ko not_active Expired - Lifetime
- 1991-08-20 FI FI913927A patent/FI108776B/fi active
- 1991-08-20 BG BG95018A patent/BG60462B1/bg unknown
- 1991-12-23 ZA ZA9110129A patent/ZA9110129B/xx unknown
1993
- 1993-09-03 US US08/116,247 patent/US5929212A/en not_active Expired - Lifetime
- 1993-09-13 GB GB9318911A patent/GB2268744B/en not_active Expired - Lifetime
1994
- 1994-06-08 AU AU64612/94A patent/AU664801B2/en not_active Expired
1995
- 1995-10-12 GR GR950402787T patent/GR3017734T3/el unknown
1997
- 1997-12-22 JP JP9353861A patent/JPH11243955A/ja active Pending
- 1997-12-24 GR GR970403432T patent/GR3025781T3/el unknown
1998
- 1998-11-23 NO NO985467A patent/NO985467D0/no not_active Application Discontinuation
- 1998-11-23 NO NO19985468A patent/NO316074B1/no not_active IP Right Cessation
1999
- 1999-04-19 FI FI990875A patent/FI109768B/fi active
2003
- 2003-11-07 US US10/703,963 patent/US7244832B2/en not_active Expired - Fee Related
- 2003-11-07 US US10/704,352 patent/US7241877B2/en not_active Expired - Fee Related
- 2003-11-07 US US10/704,071 patent/US7244615B2/en not_active Expired - Fee Related
- 2003-11-07 US US10/703,344 patent/US7262050B2/en not_active Expired - Fee Related
2004
- 2004-09-10 US US10/937,949 patent/US20050136054A1/en not_active Abandoned
- 2004-09-10 US US10/938,117 patent/US20060029593A1/en not_active Abandoned
- 2004-09-10 US US10/937,971 patent/US20050123534A1/en not_active Abandoned
2005
- 2005-11-21 US US11/284,260 patent/US20060073136A1/en not_active Abandoned
- 2005-11-21 US US11/284,261 patent/US20060073137A1/en not_active Abandoned
2021
- 2021-09-02 US US17/464,970 patent/USRE50178E1/en active Active

Also Published As

Publication number	Publication date
US20060029593A1 (en)	2006-02-09
GR3017734T3 (en)	1996-01-31
GB9117611D0 (en)	1991-10-02
US20060073136A1 (en)	2006-04-06
DE69022982D1 (de)	1995-11-16
AU6461294A (en)	1994-12-22
DE69033857T2 (de)	2002-09-12
DE69031591T2 (de)	1998-03-12
BR9007197A (pt)	1992-01-28
FI109768B (fi)	2002-10-15
CA2046904C (en)	2003-12-02
CA2046904A1 (en)	1991-06-22
HU912752D0 (en)	1992-01-28
AU631481B2 (en)	1992-11-26
ZA9110129B (en)	1993-06-23
RO114980B1 (ro)	1999-09-30
WO1991009967A1 (en)	1991-07-11
FI108917B (fi)	2002-04-30
HUT60786A (en)	1992-10-28
FI913926A0 (fi)	1991-08-20
DK0460178T3 (da)	1997-12-22
GR3025781T3 (en)	1998-03-31
KR100197956B1 (ko)	1999-06-15
RO114298B1 (ro)	1999-03-30
USRE50178E1 (en)	2024-10-22
KR100198478B1 (en)	1999-06-15
GB2268744B (en)	1994-05-11
US20060073137A1 (en)	2006-04-06
NO913271L (no)	1991-08-20
US20050202529A1 (en)	2005-09-15
BG95018A (bg)	1993-12-24
CA2050479C (en)	1997-03-25
EP0626390A1 (en)	1994-11-30
HUT58824A (en)	1992-03-30
AU7033091A (en)	1991-07-24
FI913932A0 (fi)	1991-08-20
JPH05500312A (ja)	1993-01-28
NO913228L (no)	1991-10-21
DK0460167T3 (da)	1995-11-20
NO310560B1 (no)	2001-07-23
NO316076B1 (no)	2003-12-08
NO913271D0 (no)	1991-08-20
JP3452062B2 (ja)	2003-09-29
NO985467L (no)	1991-10-21
EP0460178B1 (en)	1997-10-15
NO913228D0 (no)	1991-08-19
FI990875A0 (fi)	1999-04-19
EP0460167B1 (en)	1995-10-11
EP0460171B1 (en)	1995-06-28
DE69020544D1 (de)	1995-08-03
NO985468L (no)	1991-10-21
DK0460171T3 (da)	1995-08-28
US20040202662A1 (en)	2004-10-14
US7244615B2 (en)	2007-07-17
RO114232B1 (ro)	1999-02-26
ATE159299T1 (de)	1997-11-15
KR100191152B1 (ko)	1999-06-15
GB9117612D0 (en)	1991-11-20
EP0460171A1 (en)	1991-12-11
HU215383B (hu)	2000-03-28
NO985468D0 (no)	1998-11-23
ATE129017T1 (de)	1995-10-15
DK0626390T3 (da)	2002-03-11
HU217693B (hu)	2000-03-28
CA2037607C (en)	2005-05-24
EP0460178A1 (en)	1991-12-11
US5929212A (en)	1999-07-27
HU912751D0 (en)	1992-01-28
NO985467D0 (no)	1998-11-23
HUT58372A (en)	1992-02-28
AU6974091A (en)	1991-07-24
JPH04506458A (ja)	1992-11-12
AU646009B2 (en)	1994-02-03
FI108776B (fi)	2002-03-28
RU2112037C1 (ru)	1998-05-27
US7244832B2 (en)	2007-07-17
CA2037607A1 (en)	1992-09-07
CA2050479A1 (en)	1991-06-22
DE69031591D1 (de)	1997-11-20
GB9318911D0 (en)	1993-10-27
WO1991009966A1 (en)	1991-07-11
DE69020544T2 (de)	1996-01-18
NO913229D0 (no)	1991-08-19
GB2246781A (en)	1992-02-12
FI990875L (fi)	1999-04-19
DE69022982T2 (de)	1996-03-28
AU649645B2 (en)	1994-06-02
US20040071693A1 (en)	2004-04-15
ATE208794T1 (de)	2001-11-15
NO913229L (no)	1991-10-21
US7262050B2 (en)	2007-08-28
ES2079638T3 (es)	1996-01-16
ES2074701T3 (es)	1995-09-16
AU7048691A (en)	1991-07-24
DE69033857D1 (de)	2001-12-20
EP0620276A1 (en)	1994-10-19
JP3242913B2 (ja)	2001-12-25
JPH04505398A (ja)	1992-09-24
ES2112270T3 (es)	1998-04-01
WO1991009968A1 (en)	1991-07-11
AU664801B2 (en)	1995-11-30
US20050136054A1 (en)	2005-06-23
EP0626390B1 (en)	2001-11-14
EP0460167A1 (en)	1991-12-11
US7241877B2 (en)	2007-07-10
NO316074B1 (no)	2003-12-08
FI108777B (fi)	2002-03-28
FI913927A0 (fi)	1991-08-20
GB8928874D0 (en)	1990-02-28
ES2165864T3 (es)	2002-04-01
ATE124459T1 (de)	1995-07-15
US20050123534A1 (en)	2005-06-09
GB2268744A (en)	1994-01-19
GB2246781B (en)	1994-05-11
GB2246570B (en)	1994-05-11
GB2246570A (en)	1992-02-05
JPH11243955A (ja)	1999-09-14
US20040076627A1 (en)	2004-04-22
KR920701465A (ko)	1992-08-11